Phototoxic effect of a photosensitizer on a multidrug resistant human breast cancer cell line by Aniogo, Eric Chekwube
COPYRIGHT AND CITATION CONSIDERATIONS FOR THIS THESIS/ DISSERTATION 
o Attribution — You must give appropriate credit, provide a link to the license, and indicate if
changes were made. You may do so in any reasonable manner, but not in any way that
suggests the licensor endorses you or your use.
o NonCommercial — You may not use the material for commercial purposes.
o ShareAlike — If you remix, transform, or build upon the material, you must distribute your
contributions under the same license as the original.
How to cite this thesis 
Surname, Initial(s). (2012). Title of the thesis or dissertation (Doctoral Thesis / Master’s 
Dissertation). Johannesburg: University of Johannesburg. Available from: 
http://hdl.handle.net/102000/0002 (Accessed: 22 August 2017).    
i 
TITLE PAGE 
PHOTOTOXIC EFFECT OF A PHOTOSENSITIZER ON A MULTIDRUG 
RESISTANT HUMAN BREAST CANCER CELL LINE 
A thesis submitted to the Faculty of Health Sciences, University of Johannesburg, 
in fulfilment of the requirements for the degree of Doctor Technologiae in 
Biomedical Technology 
By 
Aniogo Eric Chekwube 
(Student number: 201504653) 
     16 November 2020 
Supervisor:       _____________________ ___________________       
     Prof. Heidi Abrahamse Date 
   16 November 2020 
Co-Supervisor:   ____________________         _____________________       
Dr. Blassan P. George Date 
ii 
 DECLARATION 
I, Aniogo Eric Chekwube, declared that this research thesis is my own unaided 
work. It is been submitted for the degree of Doctor Technologiae, Biomedical 
Technology, at the University of Johannesburg, Johannesburg. This work has not 
been submitted before for any degree or examination in any other institution.  
____________________      
Signature of candidate 
16 November 2020 




OUTPUTS OF THE STUDY 
The following Journal article publications came from this study:  
• ANIOGO E.C., George B.P. and Abrahamse H. (2019). The Role of 
Photodynamic Therapy in Multidrug Resistance Breast Cancer; A Review. Cancer 
Cell International 19: 91 (1 – 13).   
• ANIOGO E.C., George B.P. and Abrahamse H. (2020). Phototoxic Effectiveness 
of Zinc Phthalocyanine Tetrasulfonic Acid on MCF-7 Cells with Overexpressed P-
glycoprotein. Journal of Photochemistry and Photobiology B. 204: 111811 https://. 
doi: 10.1016/j.jphotobiol.2020.111811. 
• ANIOGO E.C., George B.P. and Abrahamse H. (2020). Role of Bcl-2 Family 
Proteins in Photodynamic Therapy Mediated Cell Survival and Regulation. 
Molecules 25 (22): 5308.  
• ANIOGO E.C., George B.P. and Abrahamse H. (2020). A Mechanistic Insight into 
the Apoptotic Response of Photodynamic Treatment of MCF-7 Breast Cancer Cells 
with Overexpressed P-glycoprotein. Scientific Reports (In Draft).   
 
The following Book chapter publications came from this study: 
• ANIOGO E.C., George B.P. and Abrahamse H. (2018). In Vitro P-glycoprotein 
overexpression in MCF-7 Cells, mediate Acquired Doxorubicin Chemo-resistance. 
Abstract book chapter in Medicinal plant; International Journal of Phytomedicines 
and Related Industries, first edition, Thannambikkai press, Coimbatore ISSN 
0975-4261. 
• ANIOGO E.C., George B.P. and Abrahamse H. (2020). Signal Transduction 
Interplay of Doxorubicin Resistance: Selected New Developments; Advances in 
Medicine and Biology, first edition, Nova science, New York ISBN 
9781536182934. 
• ANIOGO E.C., George B.P. and Abrahamse H. (2020). Plant-Based Compounds 
as Alternative Adjuvant Therapy for Multidrug Resistant Cells. Book Chapter in 






This work was presented at the following conferences and workshops: 
Conference / Workshop / Country and Date: International conference on Phyto 
Medicine in Coimbatore, India and was awarded best oral presentation (29th - 31st 
August 2018).  
Title of presentation: In vitro P-glycoprotein overexpression in MCF-7 Cells mediate 
Acquired Doxorubicin Chemoresistance. 
Authors: ANIOGO E.C., George B.P. and Abrahamse H. (2018) 
 
Conference / Workshop / Country and Date: International OSA Student Conference 
2018 in Johannesburg South Africa (7th – 12th October 2018).   
Title of presentation: Combined Photosensitizer and Laser Irradiation Combats 
Cancer Drug Resistance. 
Authors: ANIOGO E.C., George B.P. and Abrahamse H. (2018) 
  
Conference / Workshop / Country and Date: 2nd Biomedical Technology 
Symposium at University of Johannesburg, South Africa (7th November 2018). 
Title of presentation: Development and Characterization of MCF-7 Breast Cancer 
Cell Line with Multidrug Resistance. 
Authors: ANIOGO E.C., George B.P. and Abrahamse H. (2018) 
 
Conference / Workshop / Country and Date: African Laser Centre Student 
Conference in Stellenbosch South Africa (22nd – 30th November 2018). 
Title of presentation: In Vitro Establishment and Characterization of Acquired 
Doxorubicin Resistance in MCF-7 Breast Cancer Cells. 
Authors: ANIOGO E.C., George B.P. and Abrahamse H. (2018)  
 
Conference / Workshop / Country and Date: International Sao Paulo Advanced 
School on Biophotonics, Sao Carlos, Brazil (20 – 29th March 2019). 
Title of presentation: Phototoxic Effect of Aluminium Tetrasulfonic Phthalocyanine 
on Chemo-resistant Breast Cancer Cells. 
Authors: ANIOGO E.C., George B.P. and Abrahamse H. (2019)  
 
Conference / Workshop / Country and Date: International Siegman International 
School on Lasers, University of Rochester, New York (27th July – 3rd August 2019). 
Title of presentation: Phototoxic Effect of Aluminium Tetrasulfonic Phthalocyanine 
on Chemoresistant Breast Cancer Cells. 
Authors: ANIOGO E.C., George B.P. and Abrahamse H. (2019)  
 
Conference / Workshop / Country and Date: African Laser Student Conference, 
Stellenbosch South Africa (21 – 27th November 2019).   
Title of presentation: Phototoxic Effectiveness of Zinc Phthalocyanine on MCF-7 
cells with Overexpressed P-glycoprotein. 
Authors: ANIOGO E.C., George B.P. and Abrahamse H. (2019)  
 
Conference / Workshop / Country and Date: U21 HSG Virtual Doctoral Student 
Forum 25th August 2020.   
Title of presentation: Phototoxic Effect of Zinc Tetrasulfonic Phthalocyanine on P-
glycoprotein Overexpressed MCF-7 Breast Cancer Cells. 




• Council for Scientific and Industrial Research - African Laser Centre (CSIR-ALC) 
Scholarship, 2016 – 2020. 
• Global Excellence and Status Scholarship – University of Johannesburg, 2018 – 
2020.  
• Doctoral Merit Award – University of Johannesburg, 2018-2020.  
• Best Oral Presentation Award at the International Conference on Phytomedicine in 
Coimbatore, India, 2018. 
• UJ Finalist in the U21 & PWC Innovation Challenge 2019. 
• The Best Doctoral Journal club presenter of the year 2019. 
• Travel grant awarded to attend the São Paulo School of Advanced Science on 
Modern Topics in Biophotonics, in São Carlos, SP, Brazil, 20-29 March 2019. 
• Travel grant awarded to attend the International Siegman International School on 























Multidrug resistance (MDR) is the reason cancer treatment fails to respond to 
standard drugs. This failure has led to a major public health crisis as about 50% of 
cancers treated with chemotherapeutic drugs become resistant to the same or related 
anticancer drugs. Studies have shown that almost all cancers can develop resistance 
during treatment hence the need to develop a novel therapeutic regime. Cancer drug 
resistance is a complex phenomenon linked to increased expression of drug efflux 
proteins. These proteins include, P-glycoprotein (P-gp), breast cancer resistance 
proteins (BCRP), multidrug resistance-associated proteins (MRP) among others 
that belong to the ATP-binding cassette (ABC) transporters. It has been reported 
that repeated or continuous drug treatment upregulates efflux protein activity which 
prevents the accumulation of drugs thus contributing to drug resistance.  
Photodynamic therapy (PDT) has been shown to be a promising alternative to the 
treatment of drug-resistant tumors. The concept is based on the dynamic interaction 
between a photoactive molecule called a Photosensitizer (PS), light, and molecular 
oxygen that leads to the production of reactive oxygen species (ROS). The PS 
molecule preferentially localizes in essential cell organelles, and upon irradiation 
with a laser light, absorbs energy that initiates a photochemical reaction that leads 
to cell death. ROS production contributes to PDT cytotoxicity and promotes 
different cell death pathways like necrosis, apoptosis and autophagy and thus better 
alternative treatment for MDR cancers. 
This study aimed to develop an in vitro MCF-7 cell line with increased expression 
of P-gp and investigate the phototoxic effect of zinc phthalocyanine tetrasulfonic 
acid (ZnPcS4) photosensitizer. The MCF-7 cells with increased P-gp expression 
(MCF-7/DOX) was developed through a continuous step by step treatment of wild 
type (WT) MCF-7 cells with various concentrations (0.1 – 1 µM) of Doxorubicin 
(DOX) over a 4-month period. The surviving cells selected thereafter were 
examined using flow cytometry, immunofluorescence, and enzyme immunoassay 
for the expression of P-gp. To confirm whether zinc phthalocyanine tetrasulfonic 
acid-mediated PDT (ZnPcS4-PDT) was effective in killing MCF-7/DOX cells, we 
studied the subcellular localization, phototoxicity and mode of cell death induction 
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following ZnPcS4-PDT treatment. The flow cytometry results showed two distinct 
peaks of P-gp positive and negative expression in MCF-7/DOX cell population. 
The P-gp expression in flow cytometry analysis showed a positive significant 
(p˂0.001) correlation with the ELISA-based assay results in contrast to the control 
ME16C (Normal breast) cells.  
Prior to the examination of phototoxicity of ZnPcS4-PDT, the localization studies 
of the ZnPcS4 were conducted using the molecular probe fluorescent markers, 
Lysotracker and Mitotracker. The result showed that ZnPcS4 have a greater affinity 
for the perinuclear area of the cells with little traces of co-localization in the 
lysosomes and mitochondria. Phototoxicity results showed that the activated 
ZnPcS4 decreased the viability and proliferation of MCF-7/DOX cells as the 
concentration and dosage of light increases from 16 to 64 µM in 20 J/cm2 treatment 
groups. Cytotoxicity results showed increased lactose dehydrogenase (LDH) 
leakage from the cells, an indication of membrane damage. The cell morphology 
examination was done 24 h post-PDT treatment using the Olympus microscope. 
The results showed characteristic cell membrane damage, detachment and floating 
from the culture plate. These features were indicative of dying or dead cells and 
were seen in cells treated with 16 µM and higher concentrations of ZnPcS4. Cells 
undergoing apoptosis stained with Hoechst stain showed a gradual loss of nuclear 
architecture and condensation in a disorganized pattern. The nuclear membrane 
appeared intact in the untreated control group but slowly condensed around the 
nuclear periphery as the laser fluencies increased. 
The mode of cell death after ZnPcS4-induced PDT was analyzed using various cell 
death analysis indicators such as Annexin V/PI and Hoechst staining, DNA 
fragmentation and measurement of the expression of apoptotic proteins. The 
Annexin V/PI staining result showed the translocation of phosphatidylserine to the 
cell membrane, which suggested induction of apoptosis. Increased percentage of 
apoptotic cells were observed with laser fluence of 20 J/cm2.  
The DNA fragmentation assay result shows no DNA fragmentation which suggests 
there was no endonuclease enzyme activity nor caspase 3 involvement in the 
apoptotic process. This implies that ZnPcS4-PDT did not sufficiently activate the 
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last step in the sequence of events leading to the scission of DNA. We examined 
the pro- and antiapoptotic Bax/Bcl2 expression to assess their role and relationship 
in the initiation of apoptosis after ZnPcS4-PDT treatment. The cytochrome c release 
assays result was not significant which implied minimal photo-damage to the 
mitochondria. Subsequently, we measure the involvement of initiator caspase 8 
(extrinsic) and 9 (intrinsic) proteins to know the actual protein involved in the 
pathway. The quantitative fluorometric measurement revealed the activation of 
caspase 8 through the death receptor ligand other than the intrinsic caspases 9 
activation. The fluorometric and immunofluorescence measurement of executioner 
caspase 3 revealed a decreased and no expression, respectively. This can be justified 
by the exon deletion of CASP-3 gene in MCF-7 cells that results in abrogated 
translation of CASP-3 mRNA, thus no caspase 3 expression. The immunoreactive 
detection of p53 expression in immunofluorescence and western blotting analysis 
suggests its involvement in PDT-mediated cell death. The mutant MCF-7 cells with 
high P-gp expression showed a possibility that MCF-7 cells that survived repeated 
DOX induction of resistance might be sensitive to p53-mediated apoptosis. Hence, 
the response of resistant cells to ZnPcS4-PDT showed that the cell death was 
independent of caspase 3 activation rather due to lethal photo-damage. The study 
clearly showed that both apoptosis and phototoxicity were observed in a resistant 
phenotype of MCF-7 cells treated with ZnPcS4-PDT. However, it is important to 
state that drug response to therapy or resistance is multi-factorial besides the P-gp 
efflux proteins. Further research is recommended using genome-wide expression 
analysis technique to elucidate at gene level information about other candidate 
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Cancer is a multi-step disease that originates from a single cell with an altered 
deoxyribonucleic acid (DNA) sequence that disregards the normal rules of cell division. 
Hence, cancer can be defined as a disease that involves changes in or mutation of the 
genome. Initiation and progression of cancer depends on both internal and external 
factors such as tobacco, chemicals, radiation, infectious organisms, inherited mutations, 
hormones and immune conditions, etc. (Hejmadi, 2009a). Cancer of the breast is the 
most common cancer and the leading cause of death in women, accounting for 11.6% 
of all cancer death worldwide (Bray et al., 2018). Breast cancer is predominantly high 
in developed countries among post-menopausal women (Ghiasvand et al., 2014). 
Almost all breast cancers are carcinomas of the epithelial cells lining the ducts or 
lobules and can be treated by surgery, chemotherapy, immunotherapy and radiation 
therapy (Thompson et al., 2018, Sharma et al., 2010). The standard therapy of targeted 
chemotherapy and radiation therapy have improved patient survival and management 
over the past decades, but the major setback has been the threat of drug resistance 
(Sharma et al., 2010, Barrera-Rodríguez and Fuentes, 2015). Various chemotherapeutic 
drugs have been developed to improve the applicability in a wide spectrum of cancer 
therapy (Bergh et al., 2001). Doxorubicin, isolated from the soil bacterium called 
Streptomyces pertussis, is one of the Food and Drug Administration (FDA) approved 
drugs used for breast cancer treatment (Sochor et al., 2012, Octavia et al., 2012). It 
inhibits cancer progression by halting the topoisomerase enzyme II involved in DNA 
replication. However, this drug can develop resistance and bypass this process, which 
becomes a major challenge in achieving successful treatment. Cancer drug resistance is 
a unique process that comprises of various mechanisms thus, it is important to develop 
strategies to overcome them.   
1.2 Multidrug Cancer Resistance 
Multidrug resistance (MDR) describes a phenomenon that involves tumour cell evasion 
of cytotoxic effects of a broad-spectrum chemotherapeutic drug treatment by multiple 
mechanisms. This phenomenon can be intrinsic, when cancer cells already reveal 
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resistance to drugs at initial exposure to treatment, or acquired resistance during 
chemotherapy (Videira et al., 2014). Cancer MDR usually occurs when structurally and 
functionally unrelated drugs become inactive for cancer treatment or efflux out of the 
cells (Pokharel et al., 2014). MDR as a result of drug efflux is often attributed to the 
over-expression of certain members of ATP-binding cassette (ABC) transporter 
proteins including p-glycoprotein (P-gp), breast cancer resistance proteins and MDR-
associated proteins that are responsible to pump out the drug from the cytoplasm 
(Boichuk et al., 2017). These efflux transporters play a vital role in protecting the cell 
in physiological conditions by pumping out metabolites and their conjugates. They also 
form a unique defence network against multiple chemotherapeutic drugs as well as 
endogenous and exogenous cellular toxicants (Goler-Baron and Assaraf, 2012, Videira 
et al., 2014). MDR has been associated with cell survival during chemotherapy. This 
highlights the importance of developing a new therapeutic strategy to enable 
resensitization of resistant cancers. Photoactive molecules are used to target and 
selectively kill tumour cells. Photodynamic therapy (PDT) is one of the targeted 
treatments aimed at achieving maximum treatment response and minimum toxicity 
compared to other treatments. It has been proposed as an alternative approach in 
overcoming MDR since its mechanism is different from conventional chemotherapy 
with regards to its targeted approach and selectivity (Chen et al., 2015). However, PDT 
effectiveness on MDR phenotype largely depends on the type of photosensitizer, its 
concentration and light fluencies used (Kulbacka et al., 2010, Philchenkov et al., 2014).  
1.3 Problem Statement 
Multidrug resistance is the reason why cancer treatment with standard drugs often fails 
thus extending the duration of treatment and high costs which tend to worsen the quality 
of cancer patients life (Tanwar et al., 2014). MDR has emerged as a major threat to 
public health. Recent studies have shown that almost all cancer types have the 
capability of developing resistance to chemotherapeutic treatments due to an increased 
expression of drug efflux transporter proteins, changes in the tumour 
microenvironment, cancer stem cells, regulation of epigenetic and microRNAs, altered 
drug targets, reduced susceptibility to apoptosis and increased DNA damage repair 
mechanisms (Aniogo et al., 2019). The complexity of cancer drug resistance has led to 
the need for the design of a novel therapeutic regimen. The principle of PDT is based 
on the dynamic interaction between a photoactive molecule, light source and molecular 
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oxygen which promotes selective destruction of targeted tissues (Rocha, 2016). PDT 
has several other advantages including its usefulness in inhibiting MDR tumour cells. 
(Kessel and Erickson, 1992, Kusuzaki et al., 2000). The PDT procedure can be repeated 
multiple times with no cumulative toxic effects and can be used as a stand-alone 
treatment modality or in combination with other therapies (Capella and Capella, 2003, 
Duanmu et al., 2011). 
Evidence has shown that cancer drug resistance can lead to prolonged illness, treatment 
relapse, and even death (Wang et al., 2019). Accordingly, the GLOBOCAN 2018 has 
an estimated 18.1 million new cases with 9.6 million cancer deaths worldwide. The 
estimated incidence and mortality rates of breast cancer among all cancers were 11.6% 
and 6.6% respectively (Bray et al., 2018). Drug resistant breast cancer is also associated 
with cancer metastasis. Studies have shown that prolonged use of anticancer drugs like 
Doxorubicin, Docetaxel, Paclitaxel, and 5-fluorouracil have led to the initiation of drug 
resistance (Aniogo et al., 2019). Therefore, the identification of the mechanisms 
involved constitutes an important objective towards developing an effective strategy to 
overcome resistance.   
 
This study will address the following questions. 
1. Can multidrug resistance in a breast cancer cell line model be reversed by 
photodynamic therapy? 
2. Can photodynamic therapy trigger apoptosis in a multidrug-resistant breast cancer 
cell line? If yes, is it through the intrinsic or extrinsic apoptotic pathway?  
3. Which Bcl-2 family pro-apoptotic and caspase proteins are involved in the 












1.4 Aim of the Study 
 
This study aimed to develop an in vitro resistant MCF-7 cell line with increased 
expression of p-glycoprotein and test the phototoxicity of a novel photoactivated 
phthalocyanine tetrasulfonic acid (ZnPcS4) on the resistant cells.  
The specific objectives of the project were to: 
1 Establish and characterize a multidrug-resistant MCF-7 cell line derived from 
non-resistant MCF-7 cell line.  
2 Study the intracellular localization of a phthalocyanine-based photosensitizer 
on multidrug-resistant MCF-7 subline. 
3 Determine the phototoxic effect of a phthalocyanine-based photosensitizer on 
multidrug-resistant MCF-7 subline. 
4 Determine the mechanism of cell death and analyse the proteins involved in the 





















   
LITERATURE REVIEW 
 
2.1 Introduction to Cancer  
Cancer occurs due to collective genetic and/or non-genetic changes induced by 
environmental factors that cause alteration of certain genes leading to abnormal cell 
proliferation and neoplastic transformations (Kaplan, 2013). It occurs when there is an 
abnormal growth of cells in any parts of the body. Cancer develops after a series of 
mutations that changes the checkpoints of normal cell growth and division. (Kaplan, 
2013). About 80% of cancers are due to environmental and lifestyle changes, and hence 
are preventable. These environmental changes include, exposure to ionizing radiation, 
chemicals, biological agents like viruses, lifestyle changes such as cigarette smoking, 
excessive body weight and alcohol intake (DiPiro et al., 2014). Cancer incidence 
increases by age due to damaged DNA accumulation followed by chromosomal 
instability, the hallmark of carcinogenesis (López-Lázaro, 2015, Hassanpour and 
Dehghani, 2017). 
  
2.1.1 The Hallmarks of Cancer  
Defects due to mutation in the regulatory circuits of a cell results in the disruption of 
normal cell proliferation. Individual cell behaviour usually relies on external signals or 
the microenvironment which comprises both cellular and molecular mechanisms 
making cancer a complex disease to understand (Hejmadi, 2009b, Hanahan and 
Weinberg, 2000). This could be seen in many distinct cancer types within an organ. 
This raises the question of how normal cells transform into cancerous ones?  This 
question was answered by six multistep biological capabilities acquired during the 
cancer development (Figure 1) which includes.    
1. Ability to undergo continuous cell division and limitless replication. 
2. Ability to produce a ‘Go’ signal oncogenic growth factor. 
3. Ability to override cell ‘Stop’ signals.  
4. Ability to resist and inhibit cell death through apoptosis.  
5. Ability to undergo the production of new blood vessels.  
6. Ability to spread to other body sites through metastasis. 
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These hallmarks constitute an organizing principle that almost all cancers share. 
Underlying these hallmarks are genome mutation and instability which generates 




Figure 1:  The illustration of the six hallmarks of cancer (Hanahan and Weinberg, 2011).  
 
2.2 Cell Origin of Breast Cancer    
Breasts tissue consists of epithelial cells of the lobules and ducts that secrete and 
produce milk after childbirth (Figure 2). The  epithelium of the breast originates from 
embryonic development and undergoes changes in function, size and shape during 
puberty, pregnancy and lactation (Huebner and Ewald, 2014). The epithelium is highly 
responsive to signals that primarily lead to cancer development (Hinck and Näthke, 
2014). Tumour originates from the breast lobules and ducts when there is a change 
within the epithelial structure and function. These changes usually transform into a 
lump and evade the cell death pathways (Videira et al., 2014, Feng et al., 2018).    
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Figure 2:  Anatomy and histology of the breast (Feng et al., 2018). 
 
2.2.1 Breast Cancer Statistics  
Breast cancer (BC) is a dominant form of cancer that causes increased morbidity and 
mortality among women (Patel, 2018). The American Cancer Society (ACS) has 
estimated globally that 252, 710 breast cancer cases will be diagnosed in women with 
an approximate mortality rate of 40, 610 based on 2017statistics. This incidence and 
mortality varies with age and depends on the availability of early detection and 
treatment methods (Smith et al., 2017). BC continues to affect a significant proportion 
of South African women with an age-standardized incidence of 35 per 100,000 women. 
But due to treatment advances, increased awareness, and commitment to sustainable 
development goals, South Africa aimed at reducing premature deaths from non-
communicable diseases including cancer by 2030 (Lince-Deroche et al., 2017, Moodley 




2.2.2 Genetic Predisposition and Risk Factors of Breast Cancer   
Risk factors of BC involve genetic and lifestyle changes that include mutation of 
BRCA1 and BRCA2 genes, generally linked to 45 – 65% of breast cancer (Moyer, 
2014). Hormones like oestradiol and estrone are well-known to stimulate the growth of 
BC through oestrogen receptor alpha, whereas testosterone and 
dehydroepiandrosterone may inhibit breast cancer (Mahmud, 2008). The major genetic 
characteristics beyond individual control that influences the risk of developing BC are 
sex and age. Being a woman increases the risk 100 times compared to men and likewise 
advanced age of above 55. Beyond these two major risk factors, a hereditary factor has 
shown that the risks if woman she has a family member with the disease (Colditz et al., 
2012, Feng et al., 2018). Other risk factors include exposure to an irritant carcinogenic 
agent and lifestyle changes like the use of contraceptives, excessive alcohol, tobacco 
smoking, lack of physical activities, etc. These predisposing factors can influence and 
disrupt molecular signalling pathways and contribute to an increase in the mutations 
that cause inflammations, uncontrolled cell proliferation and metastasis (Patel, 2018, 
Anand et al., 2008).  
2.2.3 Classification and Stage of Breast Cancer  
Breast cancers are classified into two broad categories based on the origin and how it 
presents in the distinct area of the breasts which are carcinomas and sarcomas. 
Sarcomas are rare forms of breast cancer and originate from the stromal, myofibroblast 
and blood vessel components of the breast whereas the carcinomas arise from the 
epithelial component of the lobules and ducts of the breast. Carcinomas occur in various 
forms based on pathologic features and invasiveness like, non-invasive (or in situ), 
invasive, and metastatic breast cancers (Feng et al., 2018, Allison, 2012).  
1. Ductal Carcinoma In Situ (DCIS; also called intraductal carcinoma): Is a pre-
invasive, most common type of breast cancer that develops inside the pre-existing 
normal ducts. It is non-invasive but has the high potential to become invasive. Early 
screening and mammogram is important to prevent its invasiveness (Azodi et al., 
2013).   
2. Invasive Breast Cancer: This type invades and spreads outside of the normal breast 
lobules and ducts growing into other tissues and nearby lymph nodes. There are two 
forms of invasive BC, invasive ductal carcinoma and invasive lobular carcinoma 
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based on the tissue and cell type involved. Ductal carcinoma is the most common 
type comprising about 80% of all BCs and has the following subtypes: tubular 
carcinoma, medullary carcinoma, mucinous carcinoma, papillary carcinoma, and 
cribriform carcinoma. The second common type is lobular carcinoma which 
accounts for 10 – 15% of all BCs. Lobular carcinomas grow as a single cell arranged 
in a single sheet and is more diagnosed in older women (Allison, 2012, Feng et al., 
2018).    
3. Metastatic Breast Cancer: This is an advanced stage of BC that has spread to other 
body parts. Approximately 30% of women diagnosed with BC will develop the 
metastasis and this varies from person to person.  
Other sporadic forms of BCs includes; inflammatory BC, Paget disease of the breast, 
papillary carcinoma, phyllodes tumour and angiosarcoma of the breast (Feng et al., 
2018).  
When BC is suspected, a microscopic analysis of breast tissue is required to 
characterize and diagnose its molecular type. Extensive molecular studies have shown 
different biological subtypes of breast cancers with distinct behaviours and responses 
to therapy. Microarray-based expression profiling of several clusters of genes relating 
to the expression of oestrogen receptor (ER), human epidermal growth factor 2 (HER2) 
and proliferation have provided a model for the taxonomy of BC into the following 
molecular subtypes (Table 1) (Marchiò and Reis-Filho, 2008, Allison, 2012, Feng et 
al., 2018).  
1. Luminal A breast cancer: Accounts for about 70% of breast cancer and expresses 
oestrogen receptor (ER) or progesterone-receptor (PR) but not human epidermal 
growth factor receptor-2 (HER2). This type is slow growing and less aggressive 
with the best prognosis and responds well to hormonal therapy (Chekwube, 2017).  
2. Luminal B breast cancer: Accounts for 10% of BCS and is ER+ and/or PR+, 
presents high levels of dividing cells with either HER2 positive or negative. It is 
more aggressive with a bad prognosis and grow slightly faster than luminal A cancer 
(Chekwube, 2017).   
3. HER2-enriched breast cancer: The high levels of HER2 and the absence of ER or 
PR expression describe this subtype of BC. It makes up 10 – 15% of BC and grows 
aggressively with a worse prognosis than other types.  
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4. Triple-negative/basal-like breast cancer (TNBC): This type accounts for around 
20% of all BCs. It is negative for all three types of hormone receptors (ER, PR and 
HER2). TNBC is common in African American women of younger age (≤40 years) 
with BRCA1 gene mutation. It is a high-grade form of breast cancer, and usually 
more aggressive (Feng et al., 2018, Allison, 2012).  
 
































































2.2.4 Treatments of Breast Cancer  
Breast cancer treatments include; surgery, chemotherapy, immunotherapy, radiation 
and endocrine therapy (Tobias et al., 2010). These treatments are multidisciplinary and 
the choice of each depends on disease burden, risk of survival and stages of disease 
profile as determined by hormone receptor status. Women with early-stage cancer are 
best treated with breast-conserving surgery with radiotherapy or mastectomy (Moo et 
al., 2018). This treatment typically involves the excision of the tumour followed by 
adjuvant whole breast irradiation. It is a well-established treatment type for localized 
invasive breast cancer. Breast cancer with an advanced axillary staging of infection use 
neoadjuvant chemotherapy to downstage the disease and facilitates breast conservation. 
Chemotherapy is a systemic treatment that involves the administration of drugs 
typically containing both an anthracycline and a taxane to significantly reduce the rate 
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of metastasis.  Individualized treatment on hormone receptor-positive cancers and those 
with proven survival benefit use endocrine therapy (Moo et al., 2018). Generally, 
chemotherapy, radiation and targeted therapies have advanced patient survival and help 
disease management (Barrera-Rodríguez and Fuentes, 2015).  
2.3 Multidrug Resistance in Cancer 
Multidrug resistance (MDR) is a multifactorial process of tumour evasion of drug 
therapy which is a major cause of failure in cancer treatments (Wang et al., 2019). MDR 
process can originate from the innate ability of cancer cells to resist therapy during 
initial exposure (intrinsic) or, developed when tumour cells acquire resistance during 
treatment. The mechanisms involved in MDR are highlighted in Figure 3 and includes; 
(Videira et al., 2014, Pokharel et al., 2014).   
1. Overexpression of efflux proteins: these proteins are drug transporters that belong 
to the ATP-binding cassette family. They actively transport compounds in and out 
of the cell and thus facilitates resistance and protect cells from cytotoxic harm.   
2. Tumour microenvironment changes and regulation of stem cells: tumour 
microenvironment that comprises of stromal cells, extracellular matrix, cytokines 
and growth factors, all contribute to direct cell interaction mediated by drug 
resistance (Kaemmerer et al., 2020).  
3. Cell epigenetic and microRNA regulation: this involves the hyper-methylation and 
demethylation of oncogenes that leads to resistance (Mansoori et al., 2017).  
4. Drug targets modification or mutation that leads to improper binding and rapid 







Figure 3:  The mechanisms of multidrug cancer resistance. MDR is developed in tumour 
cells via increased drug efflux protein expression, modification of drug target, 
altered apoptosis, increased DNA repair, regulation of tumour microenvironment 
and epigenetic microRNA.   
 
5. Reduced susceptibility to apoptotic cell death: through increased release of B cell 
Lymphoma (Bcl-2) family proteins to inhibit the cell death process (Azmi et al., 
2011).    
6. Increased DNA damage repair mechanisms: this involves continuous proofreading 
of DNA to repair any damage or replication error capable of causing mutation 
(Figure 3) (Cree and Charlton, 2017).  
Other classifications based on cellular efflux transporter mechanisms are discussed 
below. These transporter proteins enable the cells to efflux anticancer drugs and prevent 





2.4 The ABC Drug Efflux Transporters  
The association between chemotherapeutic drugs and transporter system of cancer cells 
in relation to efflux ATP-binding cassette (ABC) transporter has emerged as one aspect 
of multidrug resistance development mechanism. Reports have emerged that during 
repeated or continuous drug treatment, cancer cells upregulate efflux transporters to 
reduce anticancer drug accumulation and therapeutic efficacy. The features and 
structure of the three main efflux transporters; P-gp, MRP and BCRP in relation to 
cancer and their cellular localization are explained below (Figure 4) (Videira et al., 
2014, Natarajan et al., 2012, Xia and Smith, 2012).  
2.4.1 P-glycoproteins (P-gp/ABCB1)  
P-glycoprotein is a well-known member of the ABC energy-dependent transporter 
protein that was identified in 1976 (Juliano and Ling, 1976). It is a 170-kDa sized 
protein located in the transmembrane layer and acts as an efflux transporter (Bao et al., 
2012). P-gp carries a variety of molecules including hydrophobic anticancer drugs 
across the membrane of the cell. P-gp comprises two transmembrane binding domains 
(TMDs) with six segments and two nucleotide-binding domains linked with N- and C- 
termini (Figure 4) (Videira et al., 2014, Binkhathlan and Lavasanifar, 2013, Hu et al., 
2016). This transporter protein is highly expressed at the blood-brain barrier, 
gastrointestinal tract, kidney and liver (Fletcher et al., 2016).  
The flexible nature of P-gp binding domain enables its interaction with diverse 
structural and chemical compounds including anticancer drugs, steroid hormones, 
hydrophobic toxic peptides (Kathawala et al., 2015, Li et al., 2016). P-gp mechanism 
of substrate efflux and transport has been explained in two different models 
(hydrophobic vacuum cleaner and lipid flippase activity). According to the vacuum 
cleaner model, any substrate/drug in contact with P-gp is partitioned in the membrane 
first before they are spontaneously translocated into the cytoplasmic leaflet. At these 
leaflets, the substrate binds to P-gp at the interior bilayer to efflux it into the 
extracellular environment. But the mechanism is different in lipid flippase activity. 
Here, once the drugs/substrates gained access to the P-gp binding site, they are flipped 
to the outer membrane leaflet of the extracellular environment. In both activity models, 
ATP utilized in the nucleotide binding domains of P-gp to form dimers that return the 
protein back to its inward conformation and the transport cycle continues (Binkhathlan 
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and Lavasanifar, 2013, Sharom, 2014). This reduces the intracellular concentrations of 
anticancer drugs or toxins in cancer cells.  
2.4.2 Multidrug Resistance-Associated Protein (MRP) 
Genetic profiling has identified and characterized Multidrug Resistance Proteins 
(MRPs) or ABCC proteins as one of the ABC transporter proteins that prevent the 
accumulation of endo/exotoxins in the cell (Dean and Allikmets, 2001). MRP 
transporter protein is composed of two nucleotides and three transmembrane binding 
domains in its structure (Figure 4) (Slot et al., 2011). The MRP family protein is divided 
into nine sub members grouped into short (MRP4, MRP5, MRP8 and ABCC12) and 
long (MRP1, MRP2, MRP3, ABCC6 and MRP7) proteins according to their TMDs 
structural composition. Similarly, these proteins utilize ATP to translocate substrates 
across the membrane. Each of the MRP transporter proteins are distributed in different 
tissues where they perform unique pharmacological and physiological functions (Leier 
et al., 1994). 
Figure 4:  The structural components of ABC transporters P-glycoprotein (P-gp), 
multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance 
protein (BCRP). P-gp and MRP1 consist of 2 nucleotide binding domains (NBD) 
and 2 transmembrane domains (TMDs) with an extra (TMD0) unique to only the 
MRP1 protein. While BCRP is composed of only 1 NBD and 1 TMD.  
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2.4.3 Breast Cancer Resistance Protein (BCRP) 
Breast cancer resistance protein (BCRP) belongs to a member of the subfamily G of the 
human ATP-binding cassette protein. It has a gene symbol of ABCG2 with 655 amino 
acid sequence that is highly expressed in renal tubular cells, placenta, blood brain 
barriers, gut and bile canaliculi (Mao and Unadkat, 2015, Litman et al., 2002). BCRP 
has a distinct feature of one nucleotide-binding domain and one transmembrane domain 
that accounts for its difference in transport mechanisms unlike the P-gp and MRPs 
(Figure 4) (Ni et al., 2010). Research has shown that both BCRP and P-gp are similar 
in terms of function and share the same substrate and inhibitor (Table 3), hence its role 
in drug resistance (Mao and Unadkat, 2015). Doyle et al. studied the role of BCRP in 
anthracycline drug resistance and therapeutic outcome in MCF-7 cells (Doyle et al., 
1998). Their findings showed a positive correlation of BCRP mRNA expression and 
BC patients response to anthracycline-based treatment (Burger et al., 2003). 
Correspondingly, Jian-Hui and group examined the expression of BCRP in over 140 
breast cancer tissue specimens treated with 5-fluorouracil and found a significant level 
of BCRP expression that mediate drug resistance  (Jian-Hui et al., 2008). This implies 
that high BCRP expression corresponds to poor clinical therapeutic outcomes. A similar 
finding was observed in acute myeloid leukaemia (Natarajan et al., 2012). Despite these 
findings, the exact mechanism of action of BCRP in cancer drug resistance is still 
vague, and more research is underway to fully understand the role in the efflux and 
excretion mechanisms that leads to cancer drug resistance (Natarajan et al., 2012). 
Some of the PSs like pheophorbide A and protoporphyrin IX have been identified as 
BCRP substrates for PDT in resistant cancer treatment (Robey et al., 2005).  
2.5 Role of Breast Cancer Stem Cell in Resistance  
Many cancers like leukaemia, lung, breast and cervical are driven by a subset of cells 
that has the capacity of self-renewal and differentiate called cancer stem cells (Korkaya 
and Malik, 2013). Breast cancer stem cells (BCSCs) have been identified as a 
subpopulation of cells that displayed expression of CD44 positive surface marker with 
stem cell-like properties of self-renewal (Kong et al., 2018). These cells formed part of 
the whole tumour bulk and are more invasive which suggest its involvement in the 
development of therapeutic resistance (Yan and Bu, 2018). The association of BCSCs 
and drug resistance involves factors ranging from increased DNA repair, epigenetic 
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regulation and decreased level of antioxidant production that help to maintain cell 
stemness. It was also reported that BCSCs often enter the quiescent stage of the cell 
cycle which makes them evade drug therapy (Rich, 2007, Diehn et al., 2009).  
2.6 Anthracycline Antibiotics in Cancer Therapy  
The anthracycline drugs are an important class of antibiotics isolated from Streptomyces 
peucetius in the 1950s by Italian and French researchers. The isolated compound from 
the microbe was found to be effective against tumour in mice and many other 
malignancies such as lymphoma, leukaemia, breast, bladder, uterine, lungs cancers. 
This compound was named as Daunorubicin which later led to the development of other 
anthracycline molecules (Fujiwara et al., 1985, Minotti et al., 2004). Doxorubicin 
(DOX) was the second in line, developed from Daunorubicin after minor structural 
changes and thus has remained the most effective and widely used cancer 
chemotherapeutic drug to date. Nevertheless, due to its shortcomings of adverse effects 
and resistance towards tumours, other analogs of Daunorubicin such as Epirubicin and 
Idarubicin with lower toxicity and wider activities were discovered (Table 2). All these 
anthracycline molecules and their derivatives have 7,8,9,10-tetrahydro-5,12-
naphthacene quinone, which serves as the basis for other anthracycline derivatives and 
contributes to antitumour activities (Faheem et al., 2013, Rizvi et al., 2018). DOX 
works by intercalating DNA to inhibit its macromolecular synthesis leading to 
topoisomerase II inhibition (Alghorabi et al., 2019). DOX has affinity for DNA and 
once attached to DNA it disrupts the replication process. It can also bind to 
topoisomerase 2β of the mitochondrial DNA to form a complex, which irreversibly 
binds to the promoters of mitochondrial genes involved in electron transport chain 
leading to mitochondrial dysfunction. In addition, DOX enhances the production of 
reactive oxygen species (ROS) by binding to cardiolipin in the inner mitochondrial 
membrane (Galán-Arriola et al., 2019). DOX is metabolized in the liver with a plasma 
half-life of 1-3 h. It has 70% plasma binding protein with 5% bioavailability and 









Table 2:  Comprehensive pharmacokinetic and dynamic details of few anthracycline drugs. 
 
Drug Name  Pharmaco-kinetics and dynamics  Structure 
Doxorubicin  Usual dosage 40 – 60 mg/m2 every 
3 – 4 weeks or 60 – 75 




60 – 70 %  
Metabolism  Doxorubicinol,  
7-deoxyaglycone 













Daunorubicin Usual dosage 30 – 45 mg/m2 daily 




60 – 70 %  
Metabolism  Daunorubicinol,  
7-deoxyaglycone 













Epirubicin Usual dosage 100 – 120 mg/m2 
every 3 – 4 weeks or 





80 %  
Metabolism  Glucuronides of 
parent compound 















Idarubicin Usual dosage 10 – 12 mg/m2 daily 




70 – 80 %  
Metabolism  1,3 – Idarubicinol  












2.6.1 Targets and Mechanisms of Doxorubicin  
DOX has several mechanisms to exert its cytocidal effects. Some are complex and 
partly understood, while others are not. One of the best-documented mechanisms is 
DNA intercalation. Perez-Arnaiz et al. showed that DOX intercalates at the 
perpendicular long axis of the DNA double helix to distort the polynucleotide structure 
formation, thus resulting in the inhibition of replication and transcription (Pérez-Arnaiz 
et al., 2014). During nucleic acid synthesis, topoisomerase II responsible for unwinding 
the double-helix structure binds to DOX and prevents the action of the polymerase 
enzymes leading to the DNA strand break and stop the replication process. Normally, 
the intercalation processes occur at the GC base-pair region with preferential toxicity 
to cells in the S-phase of the cell cycle (Pommier et al., 2010).   
DOX also exerts its anticancer effect directly by reacting with oxygen to cause 
oxidative stress. Studies have shown that DOX generates hydrogen peroxide radicals 
from oxidative reduction mediated by PARP and NAD(P)H oxidase activation. The 
radical production leads to release of apoptotic proteins that activate the process of cell 





2.6.2 Side Effects of Doxorubicin   
The efficacy of DOX in clinical use has been limited due to its severe side effects such 
as irreversible damage and toxicity to major organs and development of resistance. The 
early use of DOX encountered side effects like nausea, vomiting, stomatitis, alopecia, 
neurological and gastrointestinal disturbances. In the heart, acute DOX accumulation 
has led to ultrastructural alterations with marked interstitial oedema, perinuclear 
vacuolation, and myocardium degeneration (Yilmaz et al., 2006). DOX cannot cross 
the blood-brain barrier, thus mediates the toxicity by indirect TNF-α signalling that 
affects different cognitive domains of the brain (Tangpong et al., 2006). In the liver, 
DOX is accumulated and metabolized through the action of cytochrome P450 reductase 
enzyme to enhance ROS production hence causing an increased lipid peroxidation and 
hepatotoxicity (Carvalho et al., 2009). ROS leads to mitochondrial dysfunction and 
damage to glomerular mesangial cells of the renal system resulting in nephropathy and 
glomerular injuries (Okuda et al., 1986, Lebrecht et al., 2004). These problems of 
organ-specific toxicity have led to the development of nanosized liposome carriers 
(Doxil®) for DOX transportation to its site of action (Coelho et al., 2019). This 
formation has shown a significant reduction in toxicity compared to the free DOX 
although with induction of palmoplantar erythrodysesthesia (Barenholz, 2012, 
Kubicka-Wolkowska, 2016).  
2.6.3 Resistance Mechanisms of Doxorubicin 
Since its development and phase-I/phase-II clinical trials in 1970, DOX has been used 
as a treatment of choice for many cancers in single or a combination regime with other 
antineoplastic treatments (Kaye and Merry, 1985). When used as a single agent in 
treatment, there are limiting factors and challenges like lack of effectiveness before its 
maximum cumulative dose, toxicity effects of alopecia, vomiting, myelosuppression 
and cardiac toxicity that have limited its use. These toxicities, together with non-
response of many tumours, have contributed to the emergence of drug resistance and 
its wide clinical use (Tacar et al., 2013). The exact mechanism of resistance is not well 
understood although some early scientists have tried using in vivo murine tumour (P388 
leukaemia), Ehrlich ascites tumour and in vitro cell models (Chinese hamster ovary 
cells and C-46 murine neuroblastoma cells) to deduce anthracycline resistance 
mechanisms (Kaye and Merry, 1985). A range of human cultured cells, human small 
cell lung cancer, glioma and breast cancer cell lines have been studied both in 
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suspension and monolayer cultures (Merry et al., 1983, Shoemaker et al., 1983, Smith 
et al., 1981). The data obtained varies among the sensitive and resistant sublines of the 
same tumour (Kaye and Merry, 1985).  
The phenomenon of cross-resistance was also investigated at the same time as 
anthracycline resistance studies. Kessel and colleagues (1986) noted that vinblastine-
resistant P3815 cells were cross-resistant to Daunorubicin. This observation was 
consistent with other tumour cell lines that are sensitive to the same class of cytotoxic 
drugs despite the dissimilarities in their biological and structural activities. Hence the 
term pleiotropic drug resistance (PDR) was given to such type of cross resistance  (Kaye 
and Merry, 1985). After the discovery of the PDR phenomenon, many studies are still 
underway to elucidate the underlying mechanism of cross resistance and its possible 
translation into the clinic for patient’s benefit  (Lovitt et al., 2018).  
The way DOX is transported into the cells contributes to its mechanism of resistance. 
Some scientists believed that DOX is transported through an active carrier-mediated 
transporter system with a focus on the tumour cell membrane and its cellular matrix. A 
study has shown that resistant cancers express a cell surface glycoprotein produced by 
amplified gene expression that characterized reduced drug accumulation (Bao et al., 
2012). In addition, studies conducted with blood samples of patients with acute myeloid 
leukaemia found that there was an increase in MDR1 expression induced by 
Daunorubicin, DOX and etoposide treatment (NØrgaard et al., 1998). Contrary to this, 
Guo and colleagues (2016) reported that higher expression of the ABCC1 transporter 
proteins on MCF-7 breast cancer cells are responsible for DOX resistance. In addition 
to MDR1, MRP1 has also been found to play a part in the development of resistance to 
cancer treatments. The overexpression of MRP1 was found in breast cancer patients 
with chemotherapy resistance even when different anticancer agents are used (Chen et 
al., 2016, Goldhirsch et al., 2003). Nonetheless, a recent study on HeLa and K562 cell 
line to determine the relationship between DOX resistance and Wnt signalling pathway 
showed a decrease in MRP1 gene expression and an increase in MDR1 expression. 
These observations suggest that MDR1 protein is responsible for DOX resistance 





2.7 Photodynamic Therapy (PDT) of Cancer    
Photodynamic therapy (PDT) is a new cancer therapeutic procedure that involves 
systemic use of a photoactive molecule and light to induce the cancer cell death. PDT 
needs three components namely, a photosensitizer (PS), laser light, and molecular 
oxygen to exert the cytotoxic effects through the production of reactive oxygen radicals 
(Figure 5) (Kwiatkowski et al., 2018). PDT mechanism leads to type I and type II 
photochemical reactions through energy transfer from excited PS to tissue substrate and 




Figure 5:  The mechanism of PDT action. The PS molecule on ground state (PS) absorbs 
light energy to be excited to a singlet state (1PS*) and undergo internal conversion 
to a triplet state (3PS*). At the triplet state, the PS molecule reacts with either 
tissue substrate (Type I mechanism) or molecular oxygen (Type II mechanism) to 




The PDT process generates ROS that will cause tissue damage and signals the cell death 
process (Olsen et al., 2017, Verma et al., 2007). The extent of PDT damage on tissue 
depends on the PS type and dosage administered, PS localization, light exposure time, 
oxygen molecule that will aid photochemical reactions and many more (Abrahamse and 
Hamblin, 2016). Following PDT, occlusion of blood vessels and vascular shutdown 
occurs due to excess ROS that causes hypoxia and triggers either apoptotic or necrotic 
cell death (Oniszczuk et al., 2016, Yoo and Ha, 2012). Furthermore, PDT can also 
activate the immune system to fight and destroy tumour cells. This could also activate 
cell transduction pathways that promote apoptotic proteins and cytokine gene 
expression (Wachowska et al., 2015).  
PDT treatment efficacy depends on excess ROS production that can directly kill tumour 
cells and/or cause an inflammatory immune response with tumour vasculature 
shutdown (Postiglione et al., 2011). One of the challenges of PDT relates to PS 
accumulation and retention within the target tissue to prevent the efflux activity of 
transporter proteins. The upregulation of drug resistance proteins like, P-gp, MRPs and 
intracellular antioxidant system are some of the cytoprotective mechanisms that 
detoxify PDT-induced ROS production and result in treatment resistance (Olsen et al., 
2017). 
2.8 Components of Photodynamic Therapy  
2.8.1 Light Sources 
The light that can activate the photosensitizer (PS) for photodynamic therapy is one of 
the three components. A monochromatic coherent light source at a specific wavelength 
between 600 – 800 nm referred to as the therapeutic window are generally used in PDT 
(Agostinis et al., 2011). The required wavelength for PS activation is delivered through 
an optic fibre to prevent light reflection, transmission, scattering and enhance 
absorption (Sharman et al., 1999, Santosa and Limantara, 2008). The efficacy of PDT 
depends on penetration depth, dose, delivery mode and light fluence (Palumbo, 2007, 
Agostinis et al., 2011, Banerjee et al., 2017).  
Research has shown that incoherent light sources like halogen, fluorescent, tungsten 
and xenon lamps can be used for PDT with similar efficacy as that of laser and 
conventional lamps (Calin et al., 2011). However, lasers are highly recommended 
because of the monochromatic nature and high-power density advantages. 
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Monochromatic lasers permit irradiation with a precise wavelength which is used in 
PDT (Calin et al., 2011, Palumbo, 2007). One major disadvantage of the laser source is 
cost-related, but diode lasers are relatively inexpensive. Diode lasers are stably used in 
clinical PDT because of their relatively narrow emission spectrum and higher fluence 
rate (Agostinis et al., 2011, Oleinick et al., 2002).  
2.8.2 Photosensitiser (PS) 
PSs are light sensitive molecules that absorb light of a specific wavelength in the 
presence of oxygen to produce ROS. They have the characteristic features of chemical 
purity, stability, sensitivity, and specificity which enables them to be classified into 
first, second and third-generation PSs. PSs are combined with light in the presence of 
molecular oxygen to cause the production of cytotoxic molecules that lead to cell death 
(Robertson et al., 2009). Photofrin, a hematoporphyrin derivative is a first-generation 
PS approved for the treatment of bladder, breast, lungs, oesophageal, gastric and 
ovarian cancers. Photofrin is widely used today in the clinical setting but its limitations 
such as long-term skin phototoxicity, poor chemical composition and low activation 
wavelength led to the production of second-generation PSs (Ormond and Freeman, 
2013). To enhance the potential and clinical efficiency of PDT, second and third-
generation PSs were produced. These group of PSs, have some properties like chemical 
purity, high yield of ROS, increased photon absorption and enhanced penetration and 
retention comparably superior to photofrin (Abrahamse and Hamblin, 2016, Almeida 
et al., 2004). Almost all PS used in cancer PDT have an aromatic tetrapyrrolic 
characteristic structure similar to porphyrin with strong red or near-infrared absorption 
spectrum peak within the therapeutic window (600 to 800 nm) (Banerjee et al., 2017). 
The phthalocyanine photosensitizer is structurally related to porphyrin and exhibits 
strong absorption at 675 nm, rapid clearance and a high yield of singlet oxygen 
following PDT (Yoo and Ha, 2012). It is a planar, 18-electron heterocyclic aromatic 
molecule with four isoindole units linked by aza nitrogen atoms and a central metallic 
zinc ion as shown in Figure 6. Its extinction coefficient appears in the blue range of 105 
M-1cm-1, and a short triplet lifetime with a high triplet quantum yield of reactive singlet 
oxygen radical (Chekwube, 2017). It localises within the vital organelles of the tumour 
such as the mitochondria, lysosome, endoplasmic reticulum and Golgi apparatus 
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(Manoto et al., 2012). According to the works of Medina and colleagues in 2009, on 
isolated rat brain tumour, tetrasulfonic-activated PDT increased the cytotoxicity of the 
brain tumour (Medina et al., 2009). A similar approach was adopted by Aniogo et al. 
(2017) in the treatment of MCF-7 breast cancer cells and investigated the effectiveness 








Figure 6:  Chemical structure of Zn (II) Phthalocyanine tetrasulfonic acid (ZnPcS4) 
 
2.8.3 Phototoxic Mechanism of PDT 
The PS when administered is selectively taken up by the target tissue through enhanced 
permeability and retention effect (Shirasu et al., 2013). The PS within the cell 
transforms upon the absorption of photons by irradiation with light of an appropriate 
wavelength from a ground state to an excited singlet state. The excited PS returns to its 
ground state through fluorescence (photon emission). It can also undergo intersystem 
crossing and transform into a relatively long-lived excited triplet state molecule that 
can stimulate type I and type II photochemical reactions (Robertson et al., 2009, 
Agostinis et al., 2011). The series of energy transfer can be described using a typical 
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Jablonski diagram (Figure 7). In type I reactions, there is an exchange of a hydrogen 
atom between the excited PS and substrate to form peroxide radicals. The intermediary 
oxygen molecule is required for oxidizing the substrate in energy transfer chain 
(Oniszczuk et al., 2016, Chekwube, 2017). In type II reactions, there is an energy 
transfer interaction between the triplet excited PS and an oxygen molecule thus, leading 
to the formation of a reactive oxygen molecules. (Chekwube, 2017, Weiss, 2011, 
Banerjee et al., 2017).  
 
Figure 7: Jablonski diagram showing different energy level transfer and the production of 
singlet oxygen in type I and type II reactions in PDT mechanism of action (Calixto 
et al., 2016)  
 
The type I and II phototoxic reactive species produced together will cause tissue 
damage via cellular, vascular and immunological effects. In the cellular pathway, the 
effect of ROS formation will cause apoptosis and necrosis whereas the vascular effect 
causes vessel occlusion, collapse, dysfunction and shutdown following the PDT. This 
reduces nutrient supply to the tumour cells and thus causes autophagic cell death 
(Weiss, 2011, Chekwube, 2017, Ethirajan et al., 2011). Furthermore, phototoxic 
destruction can cause cytokine activation that will elicit immune responses. The 
immune response will lead to an acute inflammatory reaction that will attract dendritic 
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cells to take up the apoptotic cells and present them for destruction to T-cells 
(Wachowska et al., 2015, Chekwube, 2017, Castano et al., 2008). Reports have shown 
that PDT treatment can elicit a tumour-specific immune response. The plasma 
membrane damage after PDT attracts rapid infiltration of neutrophils, macrophages and 
lymphocytes which helps in the efficiency of the treatment (Korbelik and Dougherty, 
1999, Kushibiki et al., 2013). Korbelik et al. (2005) observed that PDT induced 
increased expression and release of HSP70 proteins responsible for the induction of 
inflammatory cytokine, TNF-α and other cell death signals (Korbelik et al., 2005). 
2.9 Advantages and Limitations of PDT 
The therapeutic advantage of PDT can be considered as its design and non-
invasiveness. The dynamic interactions of PS, light and oxygen results in selective 
tissue damage compared to other treatments like chemotherapy, surgery and radiation 
interventions (Rocha, 2016). With PDT treatment, there is minimal tissue toxicity, 
favourable cosmetic outcome and increased turnaround recovery time (Luo et al., 
2017). PDT requires a single treatment and can be done on an outpatient basis. It can 
be used as a stand-alone therapy or in combination with other treatment modalities like 
chemotherapy, surgery, radiotherapy etc. without any cross-reaction thus, have been 
recommended in the treatment of drug resistant cancers (Zuluaga and Lange, 2008). 
Other useful advantages include to restore the sensitivity of MDR tumour cells (Kessel 
and Erickson, 1992, Kusuzaki et al., 2000). This can be achieved in repeated treatment 
procedure with reduced cumulative toxic effects (Capella and Capella, 2003, Duanmu 
et al., 2011). 
Nonetheless, PDT has some challenges which affect the treatment efficacy like the light 
penetration index and PS localization within the cells (Oniszczuk et al., 2016). In some 
cases, endogenous chromophores like haemoglobin and melanin disturb the light 
energy delivered and thus affect the photosensitization of the PS (Sibata et al., 2000). 
PDT treatment can be used in certain localised cancer treatments but not for metastatic 
cancer because in metastatic cancer, the whole body irradiation would be required 
which is often difficult to achieve (Santosa and Limantara, 2008). PDT is also 
accompanied by sunlight toxicity caused by PS accumulation in the skin resulting in 
dryness or sunburn. Other possible side effects of PDT include photoallergic reaction, 
pain, and scab on the treated area, swelling, inflammation, nausea, and constipation 
(Santosa and Limantara, 2008, Luo et al., 2017). 
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2.10 Responses of Multidrug Resistance Cancer Cells to Photodynamic Therapy   
Accumulating evidence now suggests that PDT can be used as an alternative procedure 
for MDR cancers. This follows the unique mechanism of PDT based on PS localization 
(Mao and Unadkat, 2015). Upon irradiation, the cell organelles such as lysosomes or 
mitochondria are destroyed leading to cell death via necrosis, autophagy or apoptosis. 
The photo destruction of PDT triggers the activation of proapoptotic proteins BID 
(tBID) and translocates Bax to the outer mitochondrial membrane. This subsequently 
leads to pore formation and release of cytochrome c proteins and second 
mitochondrion-derived activator of caspases (SMAC) which activates the caspase 
proteins and results in cell death  (Figure 8) (Spring et al., 2015). 
Studies have shown that PS molecules are usually entrapped and sequestrated outside 
the cell in cancers with BCRP-rich extracellular matrix (Goler-Baron and Assaraf, 
2012). But photodamage of the protein-rich matrix increases the chances of the PS 
reaching its target site by shutting down the vasculature of the tumour supply (Goler-
Baron and Assaraf, 2012). PS molecules can also be delivered through Photochemical 
Internalization (PCI) to bypass the efflux proteins. PCI is a novel technological 
approach through which macromolecules can be delivered into the cell. It utilizes the 
same PDT principles except that the macromolecular drug delivered induces the cell 
death rather than photochemical reaction employed by PDT (Weyergang et al., 2015). 
PCI has demonstrated its effectiveness to overcome the mechanisms that circumvent 
intracellular release of anticancer agents or PS. This makes it an alternative option for 
consideration in drug resistance that are associated with efflux proteins (Weyergang et 






Figure 8:  The mechanisms of PDT response to MDR cells. The PS molecule entrapped in 
the drug efflux (P-gp and BCRP) matrix are released upon light activation into 
the cytosol where they localize in the mitochondria and lysosome. In the target 
organelles, they are activated to produce ROS-related damage that spill the 
organelle content into the cytoplasm which triggers caspase protein activation 
and cell death.         
 
Recently, the potential of PDT in killing MDR cancer and re-sensitizing them to be 
susceptible to therapy has emerged. Kusuzaki and colleagues used acridine orange as a 
photosensitizer to treat resistant mouse osteosarcoma. They observed that acridine 
orange-induced PDT had a strong significant effect unlike standard chemotherapy in 
the MDR osteosarcoma cells (Kusuzaki et al., 2000). Another study using Photofrin to 
treat MDR adenocarcinoma cells observed a positive comparable advantage in terms of 
increased oxidative stress in the resistant phenotype of the colon adenocarcinoma cells 
(Kulbacka et al., 2010). The ALA-induced PDT was used against the MCF-7 MDR 
phenotype and parental MCF-7 cells which showed increased efficacy with good 
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treatment outcome in the parental cells (Tsai et al., 2004). A similar result of increased 
efficacy was found using ALA-derivative prodrug to treat resistant MCF-7 cells 
(Feuerstein et al., 2011). A study by Chen et al. (2017) using meso-5-[p-diethylene 
triaminepenta acetic acid-aminophenyl]-10,15,20-triphenyl-porphyrin (DTP) mediated 
PDT on Adriamycin-resistant cells showed that PDT could restore the sensitivity of the 
cells to Adriamycin chemotherapy. They observed that after treatment, gene expression 
of MDR1 was reduced as a result of DTP-PDT and thus, Adriamycin sensitivity was 
restored (Chen et al., 2017). Another PS molecule, mTHPC was used by Kukcinaviciute 
and Colleagues (2017) to treat colorectal cancer that were resistant to 5-fluorouracil 
(Kukcinaviciute et al., 2017). These studies highlight the role and potential of PDT in 
multidrug resistance cancer treatment.   
2.11 Modulation of Multidrug Resistance  
Multidrug resistance modulation has been achieved through the use of MDR inhibitors 
or substrates (Li et al., 2016). Many researchers are focusing on the potential use of 
ABC transporter protein substrates/inhibitors to manage the poor treatment outcome of 
MDR cancers (Li et al., 2016). MDR transporter protein like P-gp has shown 
stimulatory and inhibitory interaction with some compounds, now classified as P-gp 
substrates and modulators (Shukla et al., 2012). The substrate molecules are actively 
transported in and out of the cell while the modulators bind and block the functional 
activities of the protein. This approach of using an inhibitor to alter MDR protein 
function has resulted in significant improvement in drug resistance cancer therapy 
outcome (Shukla et al., 2012). To date, three different generations of P-gp inhibitors 
have been developed and they include Verapamil and cyclosporine A used to inhibit P-
gp activity in leukaemia and lung cancer cells, respectively (Tsuruo et al., 1981, 
Twentyman et al., 1987). These first-generation inhibitors have some challenges of low 
therapeutic response and high toxicity which motivated the development of second-
generation inhibitors e.g. dexverapamil, valspodar and biricodar citrate. Thereafter, 
more potent third-generation inhibitors were produced, and they include Zosuquidar 
(LY335979), Elacridar (F12091), Laniquidar (R101933) and Tariquidar (XR9576) 
(Table 3) (Kelly et al., 2011, Xu et al., 2012, Li et al., 2016). These molecules can also 
be used as a chemosensitizer in combination with standard therapy to enhance the 
treatment efficacies (Kathawala et al., 2015).  
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Another possible approach is the use of microRNA, siRNAs and RNA interference in 
the reversal of multidrug resistance through inhibition of MDR gene expression. Bao 
and colleagues used the overexpression of miR-298 in resistant breast cancer cells to 
down-regulate P-gp expression and increase the nuclear accumulation of Doxorubicin 
(Bao et al., 2012). This approach is believed to target at the molecular level to prevent 
the expression of the resistant protein and its translation.   
 
Table 3:  Selected substrates and inhibitors of P-gp/ABCB1, MRP/ABCC1, and 
BCRP/ABCG2 as chemosensitizers. 
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2.12 Mechanisms of PDT-induced Cancer Cell Death  
Cell death is a fundamental biological process required for regulating the development 
and homeostasis of an organism. It can be classified as apoptotic or nonapoptotic such 
as autophagy and necrotic cell death depending on the type of stimuli and cellular 
damage (Jain et al., 2013, Tan et al., 2014). The goal of cancer therapy is to stop the 
unregulated control of cell cycle and induce cell death with minimal damage to 
surrounding normal cells (Van Herreweghe et al., 2010, Chaabane et al., 2013). By 
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eliminating abnormal or damaged cells, the homeostasis of the body cells is restored. 
The antitumor effects of PDT occur in three interdependent ways, direct tumour 
damage, damage to the vasculature and activation of the immune response. All these 
processes contribute to the overall cell death mechanisms of apoptosis, necrosis or 
autophagy. Apoptosis is a suicidal control of cell death that involves activation of 
hydrolytic enzymes leading to nuclear chromatin condensation, DNA fragmentation 
with the morphological characterization of cell shrinkage and plasma membrane 
blebbing (Edinger and Thompson, 2004). Necrotic cell death is characterized by cell 
swelling (oncosis), extensive plasma membrane damage, swelling of the cytoplasmic 
organelles and moderate chromatin condensation (Galluzzi et al., 2011). Autophagy is 
notable for its dual role processes in cell survival and its contribution to cell death. The 
latter role is characterized by extensive accumulation of double membrane autophagic 
vacuoles (autophagosomes) in the cytoplasm. PDT treatment activates proteins that 
trigger the signalling pathways for the induction of above listed cell death mechanisms. 
It is known that the interaction of light with PS and molecular oxygen leads to the 
formation of ROS. The cytotoxic response to ROS on different intracellular organelles 
triggered the phase of different cell death pathways as shown in Figure 9 (Zhu and 















Figure 9:  Different phototoxic responses of apoptotic, autophagy and necrotic cell death 





Apoptosis is a multi-step programmed cell death with a principal role in many 
physiological and pathological processes. Experiments have shown that whenever 
apoptosis is impaired, it results in the pathogenesis of disorders like cancer and 
degenerative diseases (Tan et al., 2014). Numerous studies have reported apoptosis as 
the primary target and most dominant form of cell death following PDT which can be 
induced via two major pathways: the intrinsic or mitochondria-mediated pathway and 
extrinsic or death receptor-signalling pathway (Jain et al., 2013). The fate of the two 
pathways greatly depends on the subcellular localization and the type of PS used. 
Cellular damage by apoptosis often leads to the wrapping and release of cells, internal 
components into the extracellular space to be engulfed by the body defence cells (Tan 
et al., 2014, Oniszczuk et al., 2016). The dying cell will shed off apoptotic bodies and 
presents with the following distinct cellular and morphological characteristics pyknotic 
nuclei, loss of cell-cell contact, rounding up, detachment, shrinkage, chromatin 
condensation and nuclear fragmentation (Nikoletopoulou et al., 2013, Tan et al., 2014, 
Oniszczuk et al., 2016). These characteristic features without inflammation distinguish 
apoptosis from other types of cell death (Mfouo-Tynga, 2013).  
2.12.1.1 Mitochondria-mediated Apoptosis 
Apoptotic responses to PDT are carried out primarily in the mitochondria through 
intrinsic pathway (Ortel et al., 2009). It occurs mainly when PS like photofrin and 
phthalocyanine PS derivatives are used that localize in the mitochondria. The intrinsic 
apoptotic pathway is induced by diverse factors of developmental and environmental 
causes like cellular stress, DNA damage, nutrient deprivation, and cytotoxic insult (Tait 
and Green, 2010). The first response of the pathway is the disruption of mitochondrial 
membrane potential and the release of apoptogenic proteins into the cytosol.  These 
proteins include cytochrome c, endonuclease G (EndoG) and apoptosis-inducing factor 
(AIF). The cytochrome c undergoes conformational changes to form a complex called 
apoptosome and activates the hydrolytic caspase enzymes. AIF and EndoG translocate 
from the mitochondria to the nucleus, where they mediate chromatin condensation and 
high-molecular-weight DNA fragmentation (Lorenzo and Susin, 2007, Chung et al., 
2009, Tait and Green, 2010). The caspases are a family of cysteine protease enzymes 
they are involved in the central apoptotic processes. Most apoptotic signalling process 
converges in the caspase activation which is promoted through the cleavage of a wide 
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range of cellular substrates, ultimately leading to packaging of the dying cells and their 
engulfment by phagocytes (Kurokawa and Kornbluth, 2009, Tait and Green, 2010). The 
membrane of the outer mitochondria is regulated by the B cell lymphoma 2 (Bcl-2) 
family of regulatory proteins thus, Bcl-2 proteins are the central regulators of the 
pathway. These proteins are grouped into anti-apoptotic (Bcl-2, Bcl-xL, Bcl-w, A1, and 
Mcl-1) and proapoptotic (Bax and Bak) (Youle and Strasser, 2008). Both groups of Bcl-
2 family proteins are implicated in PDT-induced apoptosis (Ortel et al., 2009). Studies 
have found that anti-apoptotic proteins are especially sensitive to ER and mitochondria 
targeted photodamage which is thus, the main functional mediator of PDT-induced 
apoptotic pathways (Yoo and Ha, 2012). Several human cancer cell lines loaded with 
phthalocyanine PS have been reported to cause photodamage with overexpression of 
Bcl-2 which enhances the apoptotic response (Almeida et al., 2004).  
2.12.1.2 Death receptor-mediated Apoptosis  
This type of apoptotic pathway occurs when photosensitizers targeting the cell 
membrane are used. The PS activation triggers specific death ligands from the tumour 
necrosis factor (TNF) superfamily (e.g., Fas ligand [FasL] or TNF-α), which interacts 
with their cell-surface receptors (Fas or TNF receptor-1 [TNFR1]) in the death domain 
of the cytoplasmic tail. One major receptor of this family is the Fas receptor which is 
actively involved in PDT induced apoptosis (Almeida et al., 2004). The Fas-associated 
death receptor form complex with FADD adaptor protein and procaspase 8 together 
called death inducing signalling complex (DISC). Upon proteolytic cleavage, caspase 
8 activates other downstream effector caspases (caspase-3 and 7) (Oleinick et al., 2002, 
Degterev and Yuan, 2008). Accordingly, this caspase activation is independent of 
cytochrome c release and mitochondrial membrane permeabilization which drives the 
intrinsic apoptotic pathway (Yoo and Ha, 2012). However, caspase 8 activated by death 
receptor signals can form a complex with Bid which rapidly translocates into the 
mitochondria and binds with the Bax or Bak of the Bcl-2 family of proteins and initiates 
apoptosis through the caspase cascade. This way the extrinsic pathway can shift to the 
intrinsic pathway through Bid activation by caspase 8 and achieve apoptosis. Bid has 
been described to be dispensable for apoptosis despite been the molecular connector 
between intrinsic and extrinsic apoptotic pathways (Zinkel et al., 2005, Kaufmann et 
al., 2007, Kodama et al., 2011).  Another similar report has stated that Bid serves as a 
guard for a mitochondrial pathway for apoptosis but how it activates the Bax and Bak 
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proteins is still unclear (Zha et al., 2000). PDT-induced death-receptor mediated 
apoptosis has been observed in many cell lines with Hypericin PS in different 
experimental settings (Almeida et al., 2004, Buytaert et al., 2007, Ortel et al., 2009). 
Similarly, both in vitro and in vivo PDT experimentation have reported to increase the 
expression of Fas death receptor and its ligand FasL (Chen et al., 2002, Oleinick et al., 
2002, Buytaert et al., 2007). Such overexpression was also observed in tumour-bearing 
mice and the formation of Fas-FADD complexes and activation of caspase-8 were also 
observed following PDT, which suggests apoptosis via death receptor mediated 
signalling (Ahmad et al., 2000, Yokota et al., 2000). PDT-induced apoptosis can also 
be influenced by other cellular signalling pathways like; calcium homeostasis, ceramide 
formation and MAPKs (Penning et al., 1992, Tong et al., 2002, Almeida et al., 2004).  
2.12.2 Autophagy 
Autophagy is a term derived from the Greek words ‘Auto and Phagy’ meaning self-
eating. Autophagy is a process of degradation of proteins and dysfunctional organelles 
to maintain cellular homeostasis (Lippai and Szatmári, 2017). It is an evolutionarily 
conserved catabolic pathway that consists of isolation of membrane, the formation of 
autophagosomes and autolysosomes. Autophagy responds to intra and extracellular 
stress signals such as starvation, pathogenic infection and depreciation of growth 
factors (Fulda et al., 2010). This pathway is activated by Beclin-1 and autophagy-
related proteins coming together to form autophagosomes and infusion with lysosome 
for degradation of the inner substances (Chien et al., 2019, Guo et al., 2012). The 
process relies on cell component degradation which is required for cancer treatment 
(Oniszczuk et al., 2016). Autophagy is crucial for cell survival under extreme 
conditions to recycle damaged constituents beyond its control. The role of autophagy 
in cancer is still controversial. While many scholars think it is required for cell survival 
(Sato et al., 2007), many others believe that it contributes to tumorigenesis (Yang et al., 
2011, Altman et al., 2011, Guo et al., 2011) and thus causes non-apoptotic type of 
programmed cell death (Yu et al., 2008, Gozuacik and Kimchi, 2004). During 
oncogenesis, autophagic activation can play a tumour suppressor role by blocking anti-
autophagic genes and activating pro-autophagic genes (Ouyang et al., 2012). Induction 
of cell death and inhibition of growth are two main targets of cancer therapy. The 
autophagic response can be mediated in three different forms, such as chaperone-
mediated autophagy, which involves the selective delivery of chaperone complexes and 
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lysosomal-associated membrane protein 2A (LAMP2A). Micro-autophagy and macro-
autophagy involve direct cytoplasmic engulfment, invagination of lysosomes and 
formation of double membrane autophagosomes. The latter forms use the cytoplasmic 
cargo mechanisms to sequester the degraded proteins in a selective and non-selective 
manner (Oniszczuk et al., 2016, Lippai and Szatmári, 2017). 
2.12.3 Necrosis 
The term necrosis refers to an accidental death of cells in response to disease, ischemic 
injury or lack of blood supply (Galluzzi et al., 2011, Wallach et al., 2016). It is the result 
of bioenergetics failure characterized by cellular swelling and rupturing due to impaired 
metabolism coinciding with the rapid depletion of ATP to a level incompatible with 
cell survival (Edinger and Thompson, 2004, Hotchkiss et al., 2009). More evidence 
now shows that necrotic cell death is a well-controlled crosstalk event among several 
biochemical, molecular and cellular activities (Festjens et al., 2006, Van Herreweghe 
et al., 2010, Jain et al., 2013). Programmed necrosis or necroptosis, is difficult to define 
because of the complex execution mechanisms and other underlying factors related to 
its regulation and molecular mechanisms (Jain et al., 2013, Chekwube, 2017). In some 
instances, it can occur in a disordered form such that it lacks the features of programmed 
cell death (i.e., apoptosis or autophagy). This indicates it is executed by specific signal 
transduction that depends on intracellular signalling mechanisms after a specific cue 
(Christofferson and Yuan, 2010, Galluzzi et al., 2011). Most intracellular events in 
necrotic cell death have shown the activation of pro-inflammatory cytokine signalling 
cascades by the spilling of cellular content (Oniszczuk et al., 2016). This event can lead 
to mitochondrial dysfunction, excessive production of ROS, depletion of ATP, 
dysfunction of calcium homeostasis, lysosomal and plasma membrane rupture, 
perinuclear clustering of organelles, activation of calpain and cathepsin proteases 
(Giusti et al., 2009). 
Advances in cancer therapy and emerging development of drug resistance have fuelled 
the search for an alternative modality to manage the rising cancer death. The only way 
to curb this challenge is to develop a novel strategy to fight and obstruct cancer drug 
resistance. Based on the literature, PDT as an emerging treatment procedure can be 
used for resistant cancer treatment. The current study showed an increased cytotoxicity 
on MCF-7/DOX cells after PDT. The photo-destruction of PDT led to the activation of 




    
MATERIALS AND METHODS 
The overview of the methodology adopted is shown in the flow diagram (Appendix A). 
The list of consumables (Appendix B), chemicals and solutions (Appendix C) used are 
provided in the Appendix section. The list of equipment used, and calculations 
performed within the methodology are provided in Appendix D and E respectively. 
Higher Degree Committee and Research Ethics Approval letter for this project was 
obtained from the Faculty of Health Sciences Research Committee of the University of 
Johannesburg (REC-241112-035) as indicated in Appendix F and G respectively. 
3.1 MCF-7 Breast Cancer Cell Line 
The human breast cancer cell line (MCF-7; ATCC HTB-22) was used as the parental 
cell line in this project. This cell line was first established in 1970 at Michigan Cancer 
Foundation by Herbert D. Soule from the pleural effusion of the chest wall nodule of 
Sister Catherine Frances (Lee et al., 2015). MCF-7 cells are popularly used for in vitro 
breast cancer studies because of its modular chromosome and genome stabilities.  
3.2 Cell Culture and Establishment of P-glycoprotein Overexpression  
The MCF-7 cells (ATCC HTB-22) used as the wild type (WT) cell line and normal 
breast cells (ME16C) used as control cell line, were both purchased from American 
Type Culture Collection (ATCC). Increased P-gp expressing cell line (MCF-7/DOX) 
otherwise referred to as DOX-variant resistant cells were established from WT cells by 
continuous exposure to increasing concentrations of Doxorubicin (0.1 – 1 µM) over a 
period of 4 months. The cells selected thereafter were further used for PDT experiment 
whereby the untreated and treated were used as control and experimental cells, 
respectively. Both the WT MCF-7 and MCF-7/DOX cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM; D5796) supplemented with 10% 
Foetal Bovine Serum (FBS, 10499-044; Gibco), 1% Penicillin-Streptomycin (P4333) 
and 1% Amphotericin B (A2942) in 85% humidified atmosphere at 37oC and 5% CO2. 
Standard cell culture procedures were followed to grow the cells in T175 culture flasks 
(CR/431080) and passaged twice at each drug concentration every 7 days. Experimental 
cells were seeded in 35 mm culture dishes at a concentration of 5x105 cells/cm2 and 
incubated for 4 h to allow the cells to attach for and homeostatic recovery. Prior to 
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experimental use, MCF-7/DOX cells were maintained in a drug-free medium and 
passaged at least two times weekly.   
3.3 Cell Culture Preparation 
The MCF-7 cells grown in complete DMEM medium were cultured in T175 flasks and 
confluency observed using inverted microscopy (Olympus CKX41). Once above 80% 
confluent, 7 mL of trypLE express were added to detach the cells and the suspension 
was aspirated into a 50 mL tube and centrifuged at 1,013 xg for 5 min at 20°C. After 
the centrifugation, the cell pellet was re-suspended in 5 mL growth medium and 10 µL 
of the suspension was used to determine the number of viable and non-viable cells per 
mL using the Trypan Blue dye exclusion assay. Thereafter, the appropriate number of 
cells (5 x 105 cells) were seeded on the 35 mm culture dishes (Corning, 430588) in 3 
mL culture medium, incubated for 4 h to allow the cells to attach and for homeostatic 
recovery before various in vitro experiments.  
3.4 Chemical Compounds and Reagents 
Doxorubicin hydrochloride (D1515; Sigma-Aldrich) was dissolved in 0.5% dimethyl 
sulfoxide (DMSO) and deionized water. The primary antibody (Anti-P-gp; ab3366; 
Abcam biotechnology, Inc) was used for ELISA, flow cytometry and 
immunofluorescence staining. Secondary antibody (Goat Anti-mouse IgG-FITC lot no: 
F23; Novus Biologicals) was used for flow cytometry and immunofluorescence. HRP-
conjugated secondary antibody (Anti-mouse immunoglobulin IgG-HRP, lot no: SC-
2005; Santa Cruz Biotechnology) was used for ELISA. Photosensitizer: Zinc (II) 
phthalocyanine tetrasulfonic acid (ZnPcS4) was purchased from Santa Cruz® 
Biotechnology (Sc-264509A). All other reagents, media and supplements used were 
listed in Appendix B.   
3.5 Characterization of P-glycoprotein Overexpression in MCF-7/DOX.  
3.5.1 Enzyme-Linked Immunosorbent Assay (ELISA)  
Cell-based ELISA technique was used to analyse the expression of P-gp. The cells were 
seeded in a 96-well plate at 2 × 104 cells per well in a total volume of 200 µL DMEM 
media and allowed to attach overnight. The plate washer (Bio-Rad, F92430) was used 
with Phosphate Buffered Saline (PBS) to wash the plate before adding 200 µL of 8% 
paraformaldehyde solution to fix the cells. The fixative solution was removed after 15 
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min incubation at 37°C, and plates were washed thrice with PBS. Thereafter, 200 µL 
of 1% permeabilization solution (Triton X-100 in PBS) was added and incubated for 
30 min at room temperature. At the end of incubation, the solution was removed and 
200 µL of 10% goat serum was added and incubated for 2 h. Plates were washed and 
100 µL of 1:1000 diluted primary antibody (Anti-P-gp; ab3366; Abcam Biotechnology, 
Inc.) was added and incubated for 2 h. Plates were washed thrice again with PBS and 
100 µL of 1:5000 diluted HRP-conjugated secondary antibody (Anti-mouse 
immunoglobulin IgG-HRP, lot no: SC-2005; Santa Cruz Biotechnology) was added and 
incubated for 2 h at room temperature. Followed by rinsing with PBS, 100 µL HRP 
substrate solution 3, 3’5, 5’-Tetramethylbenzidine (TMB) was added and incubated for 
20 min. the reaction was stopped with 100 µL 0.16 M Sulphuric acid and the intensity 
of the colour produced was measured at 450 nm with Perkin-Elmer, Victor3 multiplate 
reader.  
3.5.2 Immunofluorescence Characterization   
Cells were harvested from the T75 culture flask and seeded at 1 × 105 cells onto heat 
sterilized glass coverslips placed inside a 35 mm cell culture plate and allowed to attach 
overnight. Thereafter, cells were rinsed twice with ice-cold PBS-BSA-azide buffer 
(PBS; 0.1% w/v BSA; 0.01% w/v azide). Cells were fixed with 4% paraformaldehyde 
in PBS at pH 7.4 for 10 min at room temperature. To expose the antigenic site and 
improve the detection of antibody, the cells were covered with antigen retrieval buffer 
(EDTA Buffer; PBS, 1 mM EDTA, 0.05% Tween 20) and preheated at 95°C for 10 
min. The cells were washed thrice with PBS for 5 min and non-specific binding of the 
antibodies were blocked with 1% BSA diluted in PBS and 0.1% Tween 20 for 30 min. 
Cells were incubated with 10 µg/mL mouse monoclonal antibody (JSB-1) to P-gp 
(1:40, Anti-P-gp; ab3366; Abcam biotechnology, Inc.) in PBS-BSA-azide buffer for 1h 
at room temperature. Cells were rinsed thrice with PBS-BSA/azide buffer and 
incubated with 10 µg/mL secondary antibody conjugated with FITC (1:100, Anti-
mouse IgG-FITC lot no: F23; Novus Biologicals) in PBS-BSA-azide buffer for 1 h at 
room temperature, protected from light. Cells were rinsed thrice as before and 
counterstained with 1 mg/mL 4’-6-Diamidine-2’-Phenylindole Dihydrochloride 
(DAPI; D9542, Sigma-Aldrich) for 1 min, rinsed and mounted with fluoromount 
aqueous mounting media (F4680; Sigma-Aldrich). The slides were viewed under Carl 





3.5.3 Quantification Using Flow Cytometry  
Flow cytometry was used to investigate the P-gp expression in both WT MCF-7 and 
MCF-7/DOX cell models. The levels of P-gp expression were analysed via flow 
cytometry using BD Accuri C6 and appropriate filters. Briefly, cells were harvested 
using TrypLE express and re-suspended in approximately 2 × 106 cells/mL in ice-cold 
PBS (10% FBS, 1% sodium azide). Afterward 100 µL of cell suspension was added in 
a flow cytometric round tube. Cells were incubated with 2 µg/mL mouse monoclonal 
antibody (JSB-1) to P-gp (1:40, Anti-P-gp; ab3366; Abcam biotechnology, Inc.) in 3% 
bovine serum albumin (BSA) in PBS for 30 min at 4°C. Cells were rinsed thrice with 
3% BSA, 1% azide PBS buffer by centrifuging at 400 xg for 5 min and incubated with 
fluorescein isothiocyanate (FITC) – labelled secondary antibody (1:100, Anti-mouse 
IgG-FITC lot no: F23, Novus Biologicals) in 3% BSA in PBS for 30 min in dark at 
room temperature. Cells were rinsed thrice by centrifugation as previously mentioned 
and pellets were re-suspended in ice-cold PBS. Flow cytometry analysis was done with 
10 000 events captured per each sample.     
3.5.4 Functional Assessment Using Rhodamine 123 Accumulation Assay  
The P-gp activity were measured with Rhodamine 123 substrate. This assay measures 
the uptake, and retention of the Rho123 dye in MCF-7 and MCF-7/DOX cells in the 
presence or absence of Verapamil as previously reported by Jouan et al. (Jouan et al., 
2016). Briefly, cells were seeded in a 96-well plate at 2 × 104 cells per well in a total 
volume of 200 µL DMEM media and allowed to attach overnight. The plate was 
washed once with PBS using a plate washer (Bio-Rad, F92430) and exposed to 10 µM 
Rho123 (1% methanol, HBSS: R8004; Sigma-Aldrich) in the presence/absence of 
50 µM Verapamil (1% methanol, HBSS: V4629; Sigma-Aldrich), at 37oC for 20 min. 
Thereafter, the plate was washed three times with ice-cold PBS to remove excess 
Rho123, followed by 30 min incubation with 200 µL lysis buffer to lyse the cells. The 
intracellular level of Rho123 was quantified spectrofluorimetrically by Perkin-Elmer, 
Victor3 multiplate reader with excitation and emission wavelengths of 485 and 535 nm. 
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3.6 Light Source and Irradiation 
The MCF-7 cells were irradiated with a 680 nm diode laser (Figure 10) (MRL-III-680 
– 800 mW); S/N: 18071412; model no: PSU – III – LED; Optoelectronics Tech. Co., 
LTD; National Laser Centre of South Africa) using three different laser irradiation 
fluencies (5, 10 and 20 J/cm2). The laser power output was measured with a field-mate 
coherent power sensor detector (0496005). Other laser parameters are indicated in 
Table 4. Experimental cells within the culture dish were irradiated at 200 mW/cm2 
power output for different irradiation fluencies. The time of exposure was calculated 
using the equation: Irradiance (J/cm2) = time (s) × [power (W)/surface (cm2)] (Chen et 
al., 2008). 
 
Table 4:  Parameters of the 680 nm laser used in this study.  
Parameters  
Manufacturer Optoelectronics. Tech. Co. LTD   
Model no. PSU – III – LED (MRL-III-680 – 800 mW) 
Wavelength 680 nm  
Wave emission  Continuous  
Spot size  9.1 cm2 
Power output 200 mW/cm2 
Fluencies  5 J/cm2 
 10 J/cm2 
 20 J/cm2 
Irradiation times 3 min, 28 sec 
 6 min, 55 sec 






Figure 10.  The image of laser 680 nm diode laser used in the study.  
3.7 Photodynamic Treatment  
For photodynamic therapy, the cells were seeded at 5 × 105 cells per 35 mm culture 
dishes in complete media. The cells were attached 4 h after seeding and were treated 
with different concentrations (2 – 64 µM) of ZnPcS4 and incubated overnight in the 
dark at 37oC (5% CO2 humidified atmosphere). Thereafter, the ZnPcS4-containing 
medium was replaced with PBS, and the cells were irradiated with three different light 
doses (5, 10 and 20 J/cm2). After irradiation, PBS was removed, and the cells were 
washed with HBSS and maintained at 37oC (5% CO2 humidified atmosphere) in 
ZnPcS4-free medium for 24 h before biochemical analysis of cellular viability, 
proliferation and cytotoxicity.  
3.7.1 Intracellular ZnPcS4 Localization and Distribution   
To understand the subcellular localization and distribution of ZnPcS4, the cells were 
seeded on a coverslip and allowed to attach. The cells were attached 4 h after seeding 
and 45 µM of ZnPcS4 in complete medium was added to the cells and incubated for 4 
h. After the incubation period, the cells were washed thrice with PBS and fixed on 
coverslip with 4% paraformaldehyde at 37oC for 15 min. A co-localization technique 
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with fluorescent markers Lysotracker and Mitotracker green (molecular probes) were 
used to detect the lysosomal and mitochondrial localization of ZnPcS4. The cells were 
stained with the molecular probe for 15 min in dark and counterstained with DAPI for 
5 min. Thereafter, the cells were washed thrice and mounted on a glass slide using the 
fluoromount mounting medium. The slide was examined under a Carl Zeiss fluorescent 
microscope (Axio Observer ZI) using Cy5 emission filter.    
3.7.2 Trypan Blue Viability Assay  
Trypan blue assay (Sigma-Aldrich T8154) was used to determine the percentage 
viability of treated MCF-7/DOX cells. The cells were mixed with an equal volume (10 
µL) of trypan blue dye (Sigma Aldrich, T8154), loaded in a plastic disposable 
Countess® Cell Counting Chamber Slide and counted using Invitrogen Countess II 
Flan Automated Bench Top Cell Counter (Countess® Automated Cell Counter). This 
counting chamber determine the percentage of viable cells with intact membrane and 
non-viable/death cells that are stained with the trypan blue dye. 
   
3.7.3 ATP Metabolic Assay  
 
The Adenosine triphosphate (ATP) activity of the PDT treated cells was assessed using 
Cell Titre-Glo® luminescent viability assay (Promega G7570). This assay kit measures 
the proliferation by culture-based quantification of ATP production. Briefly, the Cell 
Titre-Glo® reconstituted reagent was mixed with an equal volume (50 µL) of treated 
cell suspension, agitated for 2 min, and incubated for 10 min in the dark. After the 
incubation, the luminescent signal formed was measured in Relative Light Units 
(RLUs), using a Multilabel counter (Perkin-Elmer, Victor3TM, 1420) corresponds to the 
amount of ATP present in the cell lysate.   
3.7.4 Cytotoxicity Assay 
Cell membrane integrity was assessed by measuring the amount of lactate 
dehydrogenase (LDH) released into the culture medium. This quantitative assay 
measures the cytosolic LDH enzyme to assess the integrity of the cellular membrane. 
The CytoTox96® nonradioactive cytotoxicity assay is dependent on tetrazolium salt 
conversion to a red formazan product, which is measured spectrophotometrically. The 
assay was performed according to the manufacturer’s protocol. Briefly, an equal 
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volume (50 µL) of the culture medium is mixed with the reconstituted reagent of 
CytoTox96® Non-Radioactive Cytotoxicity Assay (Promega G1780) in a 96 well plate 
and incubated for 30 min in the dark. Thereafter, the colorimetric compound formed 
was measured at 490 nm using a Multilabel counter (Perkin-Elmer, Victor3TM, 1420). 
3.7.5 Examination of Cellular Morphology after PDT  
Treated cells were assessed for changes in their morphology after 24 h PDT in culture 
dishes under an Olympus inverted light microscope (Wirsam, Olympus CKX41) and 
pictures were taken using the SC30 Olympus camera.  
3.8 Cell Death Analysis  
3.8.1 Annexin V/PI Apoptosis Detection Analysis  
The FITC Annexin V/PI Apoptosis detection kit II (BD PharmingenTM: 556570) was 
used according to the manufacturer’s instruction to determine the percentage of cells 
undergoing apoptosis. Briefly, after various treatments, harvested cells were washed 
twice with cold PBS in a 5 mL flow cytometer test tube and cells were suspended in 
binding buffer solution. Thereafter, 5 µL of FITC Annexin V and 5 µL of propidium 
iodide (PI) were added to the mixture. The tube containing the mixture was incubated 
at room temperature in the dark for 15 min after which the mixture was analysed using 
the blue laser filter of BD Acurri flow cytometer. 
3.8.2 Nuclear Damage Assessment using Hoechst Stain.  
To examine cell nuclear morphology, cells were grown on a glass coverslip in 35 mm 
culture dishes in complete media at a seeding density of 1 × 105 cells and performed 
photodynamic therapy using 45 µM ZnPcS4 (IC50 of 20 J/cm
2). Thereafter, the cells 
were washed twice with HBSS, fixed with 4% paraformaldehyde, permeabilized with 
0.2% Triton X -100, and stained with Hoechst 33342 (2’-[4-ethoxyphenyl]-5-[4-
methyl-1-piperazinyl]-2,5’-bi-1H-benzimidazole trihydrochloride trihydrate) stain (1 
µg/ml) at room temperature for 15 min. After the incubation, the cells were rinsed three 
times with PBS, and mounted on a glass slide using the fluoromount aqueous mounting 
medium. The slides were viewed under a Carl Zeiss fluorescent microscope (Axio 





3.8.3 DNA fragmentation Analysis (Gel Electrophoresis) 
This is a semi-quantitative method of measuring apoptosis. It detects the 
internucleosomal DNA fragmentation, which is the hallmark of apoptosis in 
mammalian cells. This assay is done according to the manufacturer’s (ab66090; 
Abcam®) guide. Briefly, after the treatment, cells were lysed with 35 µL of TE lysis 
buffer by gentle pipetting and 5 µL of enzyme A solution was added and incubated for 
10 mins at 37°C. After the incubation, enzyme B (5 µL) was added and incubated at 
50°C overnight. Next, 5 µL of ammonium acetate solution was added together with 
50 µL of isopropanol, mixed and kept at -20°C for 10 mins. The mixture was 
centrifuged at 300 xg for 10 mins to precipitate the DNA and the supernatant was 
removed. A volume of 0.5 mL of 70% ethanol was used to wash the DNA and the 
resultant pellet was dissolved in 30 µL DNA suspension buffer. The DNA suspension 
and molecular weight size marker (Bio-33053 HyperLadderTm 1kb Bioline) was later 
resuspended in 20 µL of Tris acetate EDTA buffer and electrophoresed on 1.2% agarose 
gel containing 0.5 µg/ml ethidium bromide. The stained gel was visualized by Trans-
illumination with UV light and photographed. 
3.8.4 Enzyme-linked Immunosorbent Assay for Bcl-2 and Bax Proteins 
Detection 
ELISA was used to detect and quantify the expression of Bcl-2 and Bax apoptotic 
proteins involved in the cell death pathway. The human Simple-Step Bcl-2 ELISA Kit 
(ab202411) and human Simple-Step Bax ELISA Kit (ab199080) from Abcam are 
designed for the quantitative measurement of these proteins in human cells and tissue 
extracts. The kit is provided in such a way that the affinity tag labelled captured 
antibody and a reporter conjugated detector antibody are mixed and the entire complex 
(capture antibody/analyte/detector antibody) is immobilized on the 96 well plate. The 
assay was performed according to the manufacturer’s instructions. Briefly, 50 µL of 
samples and standards were added in the appropriate wells on a 96 well plate. Then 
another 50 µL of the antibody cocktail containing the appropriate antibody was added 
to the wells and the plate incubated for 1 h at room temperature on a plate shaker set at 
400 rpm. Thereafter, each well was washed three times with 350 µL of 1 X wash buffer. 
Then 100 µL of Tetramethylbenzidine (TMB) substrate was added and incubated for 
10 min in the dark. After the incubation, 100 µL of stop solution was added to each 
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well and agitated for 1 min before the optical density measurement at 450 nm using 
Multilabel counter (Perkin-Elmer, Victor3TM, 1420). 
3.8.5 Enzyme-Linked Immunosorbent Assay for Cytochrome c Protein 
Detection 
The cytochrome c ELISA kit (Cat # KH01051) was used to detect and quantify the level 
of cytochrome c. The kit is provided in such a way that the affinity tag labelled captured 
antibody and a reporter conjugated detector antibody are mixed and the entire complex 
(capture antibody/analyte/detector antibody) is immobilized on the 96 well plate. The 
assay was performed according to the manufacturer’s instruction. Briefly, 100 µL of 
samples and standards were added in the appropriate wells on a 96 well plate. Then 100 
µL of biotin conjugate solution added to the wells and the plate incubated for 1 h at 
room temperature on a plate shaker set at 400 rpm. Thereafter, each well was washed 
three times with 350 µL of 1 X wash buffer and 100 µL of 1 X streptavidin-HRP 
solution was added and incubated for 30 mins. The plates were washed four times 1 X 
wash solution. About 100 µL of stabilized chromogen was added and incubated for 30 
min in the dark. Finally, 100 µL of stop solution was added to each well, shake for 1 
min and the optical density was recorded at 450 nm using Multilabel counter (Perkin-
Elmer, Victor3TM, 1420). 
3.8.6 Fluorometric Measurement of Caspase 3, 8 and 9  
This is a multiplex assay kit (ab219915) from Abcam that provides a simple and 
convenient tool for the quantification of caspase 3, caspase 8 and caspase 9 activity in 
cells undergoing apoptosis. Briefly, the cell pellet in culture media was added at a 
concentration of 2 × 105 cells/90 µL per well in a black poly-d-lysine coated plate. The 
solution was mixed with 100 µL of each caspase assay loading solution and the plate 
was incubated for 60 min at room temperature protected from light. Thereafter, Perkin-
Elmer, Victor3TM, 1420 was used to monitor the fluorescence at the following specific 
wavelengths, caspase 3: 535 nm excitation/ 620 nm emission, caspase 8: 490 nm 
excitation/ 525 nm emission, caspase 9: 370 nm excitation/ 450 nm emission. The 
fluorescent intensity was determined using the relative fluorescence unit (RFU). 
3.8.7 Immunofluorescence of p53 and Caspase 3 
The Immunofluorescent expression of p53 and caspase 3 apoptotic proteins was 
detected using the fluorescence microscopy. This is a qualitative assay in which 1 × 105 
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cells were grown on a glass coverslip overnight. Thereafter, the cells were fixed with 
4% paraformaldehyde, permeabilized with 0.1% triton X-100 in PBS and blocked for 
non-specific binding with 10% BSA in PBS. After the blocking step, immunostaining 
of the cells was performed with monoclonal primary antibodies (1:100, anti-p53; 
CBL404 Merck company and 1:100, anti-caspase 3; AB3623 sigma-Aldrich). The 
slides were rinsed three times with PBS and incubated for 1 h at room temperature with 
a secondary fluorescent-labelled antibody (1:500, Goat Anti-mouse (FITC), ab97050, 
Abcam) which binds to the primary antibodies. Next, the nuclei of the cells were 
counterstained with 1 µg/mL 4′,6-diamidino-2-phenylindole (DAPI) and the coverslip 
was mounted on a glass slide. The protein expression was observed under the Carl Zeiss 
Axio Observer ZI fluorescent microscope.  
3.8.8 Western Blot Analysis of p53 and Caspase 3  
The concentration of proteins in cell lysates were assessed using BCA protein assay 
reagent (Thermo Fisher Scientific, Rockford, IL, USA). Depending on protein 
concentration, the cell lysates were diluted in RIPA buffer to the gel-loading protein 
concentration (2.5 µg/µL), mixed with an equal volume of sample buffer (0.125 M 
Tris/HCl pH 6.8, 10% glycerol, 4% SDS, 0.25 M DTT) and heated for 5 – 7 min at 
110°C. Protein samples were separated using protein electrophoresis (Bio-Rad, 
Hercules, CA). The proteins separated by SDS-PAGE were transferred to PVDF 
membrane Immuno-Blot (Bio-Rad Cat: 162-0177) overnight at 20 V, using a semi Dry 
blotter (Sigma-B2529). The membrane was blocked with 5% BSA in TBS for 15 – 20 
min and incubated with respective antibodies (1:100, anti-p53; CBL404 Merck 
company; 1:100, anti-caspase 3; AB3623 sigma-Aldrich; and GAPDH – mouse 
monoclonal antibody, Cat # MA5-15738, Invitrogen) for 1 h. After incubation, the 
membrane was washed three times (5 – 10 min) with TBS containing 0.1% Tween-20 
and incubated for 2 h with the horseradish peroxidase conjugated secondary antibody 
(Goat anti-mouse HRP, Cat # SC-2005, Santa Cruz Biotechnology). Afterward, the 
membrane was washed three times with TBS and the chemiluminescence signal was 
detected by adding an equal volume of ECL western blotting detection reagent 
(Amersham Cat no: RPN2209), kept in dark for 5 min, and the bands developed were 





3.9 Statistical Analysis 
The experiments were performed in duplicates in at least four independent repeats 
(n=4). The untreated control cells were used to compare the treated cells in a one-way 
ANOVA statistical analysis (Dunnett test) to determine the difference. Data were 
represented as mean ± standard error of the mean (SEM). The statistical significance 
defined as p-value less than 0.05 (*), 0.01 (**) and 0.001 (***) was examined using 




























4.1 Establishment and Morphological Changes of MCF-7/DOX Cell Lines    
The over-expression of P-gp in MCF-7 cells was induced by repeated treatment of the 
WT cell line with different concentrations of Doxorubicin. During the treatment, the 
cells undergo some morphological changes as different doses of DOX were applied. 
One characteristic feature observed in the DOX resistant cells was increased cell size 
from 16.93 µM of WT MCF-7 to 25.28 µM of MCF-7/DOX cells (recorded with 
Countess® Automated Cell Counter). The WT cell line retained the characteristic 
epithelial-like structure while the MCF-7/DOX cells showed a slight alteration in the 




Figure 11.  Morphology of MCF-7 and its DOX resistant subline (MCF-7/DOX). The MCF-
7/DOX subline showed morphological changes in terms of membrane alteration 
and look more of mesenchymal like formation with increased cell size that are 
distinct from the parental MCF-7 cells (Magnification 200X and scale bar: 






4.2 Characterization of P-glycoprotein Expression  
4.2.1 Enzyme-Linked Immunosorbent Assay (ELISA) 
The development of drug resistance and overexpression of membrane P-gp is one of 
the phenotypic characteristics of many drug-resistant cell lines. In this study, we 
evaluated the expression of P-gp with a cell-based ELISA method (Figure 12). The 
results showed no significant difference in the expression of P-gp between MCF-7 and 
the corresponding normal breast cells (ME16C). However, the level of P-gp expression 
was found to be significantly high (p ˂  0.001) in MCF-7/DOX cells which could be due 
to the continuous exposure of the cells to DOX chemotherapy.   
 
Figure 12.  P-glycoprotein (P-gp) expression by Enzyme-linked immunosorbent assay. 
Results showed that expression of P-gp is higher (*** p˂0.001) in the MCF-7/DOX 
subline group compared to normal breast (ME16C) cells. There is no statistically 
significant difference between ME16C and wild type (WT) MCF-7 cells. Data 








4.2.2 Immunofluorescence Characterization of MCF-7/DOX Resistant Cells 
After the detection of P-gp, we characterized the expression of transporter protein using 
the immunofluorescence staining method. Positive MCF-7/DOX cells expressed P-gp 
(green colour signals) as seen in Figure 13. Whereas the expression of P-gp in WT 
MCF-7 cells was faint hence, characterized as weak expression (no/reduced green 
signal). These results were in accordance with the ELISA P-gp expression method, 
which necessitate the investigation for functional assessment of the efflux protein 
activity.    
 
Figure 13.  Immunofluorescence microscopy detection assay. Analysis of wild type (WT) 
MCF-7 and resistant MCF-7/DOX cells using fluorescence microscopy showed 
positive expression of P-glycoprotein (green) in MCF-7/DOX cells. The nuclei of 
the cells were counterstained by DAPI (blue) (Magnification 400X and scale bar 
100 µm).  
 
4.2.3 Quantification of P-glycoprotein Expression by Flow Cytometry  
At the protein level, P-gp expression were quantitatively examined with flow cytometry 
to identify the subpopulation of cells with positive expression. Monoclonal antibody 
used originated from the distinct JSB-1 clone specific to MDR1 isoform of P-gp found 
in the plasma membrane. Representative histograms of positive and negative cell 
populations of P-gp expression in MCF-7 and MCF-7/DOX cells were shown in Figure 
14. As seen in the flow cytometry plot, the WT MCF-7 cells showed only one relative 
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peak for P-gp negative cells whereas, in the MCF-7/DOX cell population, two distinct 
peaks observed for positive and negative P-gp expression. Graphical representation (bar 
chart) of the flow cytometry data showing the average of three independent experiments 
analysed using the student paired t-test presented a statistically significant difference (p 
˂ 0.0034) when both cells are compared.   
 
 
Figure 14.  Expression of P-glycoprotein (P-gp) by flow cytometry. Flow cytometry profiling 
of P-gp positive sub-population represented as peak of line graph in wild type 
(WT) MCF-7 cells (1a & 1b), resistant MCF-7/DOX (2a & 2b) and bar chart 
representation of the flow cytometry data (3) showing the average of three 
independent experiments analysed using the student paired t-test presented a 
statistically significant difference (** p˂0.0034).   
 
4.2.4 P-glycoprotein Rhodamine 123 Accumulation Activity in MCF-7/DOX 
Cells 
Rho123 dye is a recognized P-gp substrate and can be used as a P-gp probe. In this 
assay, we confirmed the inhibitory potential of P-gp in MCF-7/DOX cells with Rho123 
in the presence or absence of Verapamil. As shown in Figure 15, MCF-7/DOX cells 
showed poor accumulation and retention of Rho123. The active efflux of the fluorescent 
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dye is a consequence of the active P-gp pumping action. In the presence of Verapamil, 
there was increased P-gp activity and accumulation of Rho123 dye in both cell lines. 
This observation contrasted with the absence of Verapamil, which reduced and 
prevented the intracellular accumulation of the Rho123 dye to a significant level 
(p<0.05) in MCF-7/DOX cells.       
 
Figure 15.  P-glycoprotein (P-gp) activity of Rhodamine 123 (Rho123) accumulation in wild 
type (WT) MCF-7 and resistant MCF-7/DOX cells in the presence and absence of 
a P-gp inhibitor Verapamil. The absence of Verapamil significantly reduced the 
accumulation of Rho123 in MCF-7/DOX cells compared to WT MCF-7 cells. Data 
represents a duplicate experiment of four independent repeats (n=4) with a 
significant difference at * p˂0.05. 
 
4.3 Intracellular ZnPcS4 Localization and Distribution   
The intracellular ZnPcS4 distribution in MCF-7/DOX cells was monitored with 
fluorescence microscopy after the cells were incubated with 45 µM ZnPcS4 for 4 h and 
then stained with organelle-specific molecular probes. As shown in Figure 16, the green 
fluorescence emitted by the Lysotracker was stronger than Mitotracker molecular 
probe. DAPI blue was used for the nuclei while the red fluorescence was from the 
photosensitizer ZnPcS4. The overlay fluorescence was obtained from the combination 
of red and traces of green fluorescence, which was seen in the merged image. This 
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demonstrated that ZnPcS4 has some affinity to lysosome, which might suggest the 
photo-induced cell death pathway.  
 
Figure 16.  Intracellular ZnPcS4 localization in MCF-7/DOX cells. The mitochondria and 
lysosomes were stained with molecular probes (Mitotracker and Lysotracker, 
green fluorescence/FITC). Nuclei were stained with DAPI (blue fluorescence) and 
the ZnPcS4 autofluorescence can be detected in the Cy5 channel (Red 
fluorescence). The merged image showed the overlay of green and red 
fluorescence indicative of ZnPcS4 co-localization with either the mitochondria or 
the lysosomes (Magnification 400X oil immersion and scale bar 20 µm).   
 
4.4 Determination of ZnPcS4-induced Phototoxicity 
Changes for LDH released from MCF-7/DOX cells after the treatment with 
photoactivated ZnPcS4-PDT (2 – 64 µM) were analysed using the CytoTox96® 
nonradioactive cytotoxicity assay. The results showed a dose-dependent effect, and a 
significant difference (p˂0.05) was seen at the highest ZnPcS4 concentration (64 µM) 
with 10 J/cm2. The photodamaged effect of ZnPcS4-PDT was more distinct as the dose 
of laser light was increased to 20 J/cm2 (Table 5). As the concentration of ZnPcS4 
increased to 16 µM and above at 20 J/cm2 experimental group, the increased leakage of 
LDH was observed to a significant level in comparison with the untreated control. Here, 





Table 5:  The phototoxicity of ZnPcS4-PDT with different concentrations (2 – 64 µM) and 
light fluencies (5, 10 and 20 J/cm2). The results showed a dose dependent 
treatment effect as significant difference (*p˂0.05) were seen with the highest 
ZnPcS4 concentration (64 µM) with 10 J/cm2. Data are presented as the mean ± 
SE from four independent duplicate experiments. 
Concentrations of ZnPcS4 
LDH Cytotoxicity Assay 
(Absorbance at 490 nm) 
Control 
(0 µM) 
2 µM 4 µM 8 µM 16 µM 32 µM 64 µM 














































4.5 Metabolic ATP Production  
Most cancer treatments aim at preventing the proliferation of malignant cells. A 
decrease in ATP production was observed with all ZnPcS4-PDT treated cells. 
MCF-7/DOX cells displayed different metabolic activities with different doses of 
laser light and concentrations of ZnPcS4. Our results revealed that when 10 or 20 
J/cm2 of light was used, the cells showed low ATP level as shown in Figure 17.  
 
Figure 17.  ATP metabolic activity of MCF-7/DOX cells at different concentrations (2 – 
64 µM) with different light fluencies 5 J/cm2 (A), 10 J/cm2 (B) and 20 J/cm2 
(C). Cellular ATP production significantly decreased in a dose-dependent 
trend with different concentrations of ZnPcS4 used except for 5 J/cm2 
fluency. The amount of ATP was measured by luminescence in relative light 
units (RLUs) and data are presented as the mean ± SE from four independent 





These two laser fluencies and the corresponding ZnPcS4 doses might be optimal to 
yield decreased production of ATP in MCF-7/DOX cells. Lower concentration of 
ZnPcS4 at 2, 4 and 8 µM with laser dose of 5 J/cm2, showed no significant 
difference.    
4.6 Trypan Blue Dye Exclusion Assay  
The trypan blue assay results showed the viability of MCF-7/DOX cells treated with 
ZnPcS4-PDT. It measures the percentage proportion of viable and damaged/dead 
cells. The result showed a decrease in cell viability after 24 h treatment, which is 
dependent on the laser fluencies and drug doses, used (Figure 18).  
 
 
Figure 18.  Trypan blue cell viability assay of MCF-7/DOX cells treated with ZnPcS4-
induced PDT at different concentrations (2 – 64 µM) and light fluencies (5 
J/cm2, 10 J/cm2 and 20 J/cm2). Cellular viability decreased as the 
concentration of ZnPcS4 increases. Data are presented as the mean ± SE 




The fluence that showed an optimal concentration (IC50) was 20 J/cm
2 at 45 µM. 
The 5 and 10 J/cm2 fluence experimental groups with the different concentrations 
used were not enough to cause a fifty percent inhibitory effect on MCF-7/DOX 
cells. Hence, 45 µM of ZnPcS4 was used further to investigate cellular death 
pathways.   
4.7 Examination of Cellular Morphology after PDT  
The cell morphology results obtained 24 h post-PDT showed characteristic visible 
cell structure changes such as membrane distortion, rounding-up, detachment from 
culture plate, and floating of MCF-7/DOX cells, indicative of cell death at 16 µM 
and above doses of ZnPcS4. The untreated MCF-7/DOX cells presented a normal 





Figure 19.  Morphology of MCF-7/DOX cells overexpressing P-glycoprotein treated with 
zinc phthalocyanine photosensitizer at different fluencies (5, 10, 20 J/cm2) 
using a 680 nm diode laser. The cells showed a concentration dependent 
damage to the cellular structure and shape at all three laser fluencies used. 
As the dose increases to 32 µM, the cells started rounding up and floating in 





4.8 Cell Death Analysis 
4.8.1 Annexin V/PI Staining 
This assay was performed to determine the apoptotic cell death induction by 
ZnPcS4-PDT treatment of MCF-7/DOX cells. The flow cytometry results showing 
different phases of apoptosis of untreated control and experimental cell groups were 
analysed and shown in Figure 20. The data showed an increase in the number of 
cells undergoing early apoptosis. The ZnPcS4-induced apoptotic response was 
dependent on the dose of laser fluence applied, as there was an increased number 
of cells undergoing apoptosis when 20 J/cm2 was used compared to the 5 or 10 
J/cm2 fluencies. There was a statistically significant difference (p<0.006) in the rate 
of cell undergoes apoptosis between control and 20 J/ treated group.  
 
 
Figure 20:  Cell apoptosis analysed using flow cytometry after 24 h post-treatment for 
control, 5, 10 and 20 J/cm2 treatment groups. Data are presented as 
representative graphs in different phases of apoptosis. There was a 
statistically significant difference (p<0.006) in the rate of cell undergo 
apoptosis between control and 20 J/ treated group. Data are presented as the 
mean ± standard deviation.  
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The rate of late apoptotic cell counts was greatly reduced and there was no 
difference between the untreated MCF-7/DOX control cells and other (5, 10, and 
20 J/cm2) experimental groups. Apoptosis is a time-dependent process and there 
was an increase in the early apoptotic cell counts but not in the late stage. The 
untreated control cells were used to statistically compare the results of apoptotic 
(early and late) cells undergoing cell death.  
4.8.2 Hoechst Nuclear Staining 
The nuclear morphology changes in MCF-7/DOX cells were examined using 
Hoechst 33342 staining 24 h post-treatment. The treated cells displayed a relatively 
weak and irregular blue fluorescence among various experimental groups compared 
to the untreated control cells. The nuclei of the treated groups became shrunken, 
irregular in shape and smaller as the laser fluence increased (Figure 21).  
 
Figure 21.  Nuclear morphology assessment using Hoechst 33342 staining. Nuclear 
condensation of MCF-7/DOX cells after ZnPcS4-induced PDT treatment 
with 5, 10 and 20 J/cm2 was visualized under fluorescent microscope. 
(Magnification 400X and scale bar 20 µm). 
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The irregular nuclear membrane also appeared smaller with masses of condensed 
chromatin features around the nuclear periphery. These characteristic features are 
indicative of nuclear damage. 
4.8.3 DNA Fragmentation Assay 
The DNA fragmentation assay experiment was conducted to analyse the extent of 
DNA damage and oligonucleosomal fragmentation, which contributes to cell 
apoptosis. The results showed no fragmentation of the DNA after ZnPcS4-induced 
PDT with different laser fluencies on MCF-7/DOX cells. Figure 22 displayed the 
total amount of DNA in control (lane 2) as well as treated experimental groups (lane 
3, 4, 5 representing 5, 10 and 20 J/cm2) respectively did not show a typical ladder 
formation or oligonucleosomal fragmentation. Lane 1 and 6 were loaded with DNA 









Figure 22:  Agarose gel electrophoresis of genomic DNA extracted from MCF-7/DOX 
cells after ZnPcS4 – PDT treatment. Lane 1 and 6, were loaded with DNA 
hyper-ladder, lane 2 was loaded with untreated control, lane 3, 4, and 5 with 
5, 10 and 20 J/cm2 fluence treatments with ZnPcS4 – induced PDT, 






4.8.4 ELISA of Bcl-2 and Bax Protein 
The photodamage and activation of Bax/Bcl-2 apoptotic protein family was 
measured using enzyme-linked immunosorbent assay. The results showed 
increased Bax relative to Bcl-2 protein expression (Figure 23). The amount of Bax 
expressed in control cells were 2.69 ng/mL and that of the experimental treated 
groups were 2.71, 2.73, 2.72 ng/mL for 5, 10 and 20 J/cm2 respectively. The same 
pattern of observation was seen in Bcl-2 expression (1.12 ng/mL in control and 1.23 
ng/mL in the 20 J/cm2 treatment). This showed that there was no statistically 
significant difference in the expression of Bax and Bcl-2 proteins. Hence, the 
ZnPcS4-mediated photodamage of mitochondrial Bax/Bcl-2 proteins were not seen 
on the treated cells compared with their untreated controls.  
 
Figure 23:  The enzyme immunoassay measurement of Bax and Bcl-2 apoptotic proteins. 
There is increased expression of the proapoptotic Bax compared to Bcl-2 








4.8.5 ELISA of Cytochrome c Protein 
The level of cytochrome c in the cytosol after 24 h ZnPcS4-PDT were measured 
using an enzyme immunoassay. The amount of cytochrome c released was almost 
the same (between 0.22 and 0.23 ng/mL) for untreated control and highest fluency 
(20 J/cm2) treated group (Figure 24). This result showed there was no significant 




Figure 24:  MCF-7/DOX cells treated with ZnPcS4-PDT at different fluencies (5, 10, 20 
J/cm2) were assayed for cytochrome c release from mitochondria. The level 
of cytochrome c was consistent across all treated groups, and in untreated 
control group. There was no statistical difference among the treated groups.  
 
4.8.6 Fluorometric Measurement of Caspase 3, 8 and 9 
The expression of initiator caspase 8 (extrinsic), caspase 9 (intrinsic) and 
executioner caspase 3 was measured using the fluorogenic indicators, R110 (green 
fluorescence), AMC (blue fluorescence), and ProRed (red fluorescence) 
respectively in MCF-7/DOX cells undergoing apoptosis. After ZnPcS4-PDT, a 
significant difference (p<0.037) in caspase 3 activity was observed in 5 J/cm2 and 
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20 J/cm2 (p<0.0001) in comparison with the untreated control (Figure 25). A similar 
observation was recorded with caspase 8 as the fluence of the laser treatment 
increases, caspase 8 activity also increased in a dose dependent significant manner 
with the p values, p<0.01, p<0.001 and p<0.0006 for 5, 10, 20 J/cm2 treated groups 
compared to the untreated control. Whereas in caspase 9 activity, there was no 
significant correlation among the experimental treated groups (5, 10, 20 J/cm2) but 
when analysed with control, a statistical difference (p<0.05) was seen. These results 
together showed that ZnPcS4-induced PDT increased caspase 8 activity followed 
by a slight caspase 9 activity in MCF-7/DOX cells.     
 
 
Figure 25:  Fluorometric measurement of caspase 3, 8 and 9 activity in MCF-7/DOX 
cells. After ZnPcS4-PDT, caspase 3 activity was significantly (p<0.037 and 
p<0.001 respectively) increased in 5 and 20 J/cm2 in relation to the control. 
Caspase 8 activity was increased significantly p<0.01, p<0.001 and p<0.0006 
in a fluence dependent manner for 5, 10, 20 J/cm2 respectively. Whereas, 
caspase 9 activity, showed a significant (p<0.05) difference in all experimental 







4.8.7 Immunofluorescence of p53 and Caspase 3 
The central role of tumour suppressor protein p53, and executioner caspase 3 in 
apoptosis induction after ZnPcS4-PDT were analysed using the 
immunofluorescence protein expression technique. In response to the ZnPcS4 – 
PDT, the p53 expression (pink) were seen within the nuclear matrix (blue) of the 
MCF-7/DOX cells (Figure 26). There was an increase in the expression of p53 
among the experimental treated groups (5, 10 and 20 J/cm2) which mediates the 
response of p53 to the radiation, DNA damage, oxidative stress, and hypoxia stimuli 
of ZnPcS4-PDT treatment. The expression of executioner caspase 3 in MCF-
7/DOX cells response to ZnPcS4-PDT was also investigated and the result showed 
that there was no detection of caspase 3 on the treated experimental groups, even in 
the control. The blue DAPI stain used for the nuclei was seen which corresponds to 
the staining of the nuclei. This result showed that apoptotic induction by ZnPcS4-
PDT treatment was independent of caspase 3 executioner protein.  
 
Figure 26:  Evaluation of p53 and caspase 3 expression in MCF-7/DOX cells treated 






4.8.8 Western Blotting Analysis of p53 and Caspase 3 Proteins 
The specificity of the central effector caspase 3 protein and tumour suppressor p53 
protein was measured using immunoblotting technique in MCF-7/DOX cells 
undergoing apoptosis. These proteins play a central role in the coordination of 
cellular responses to PDT-induced stress. There was a detectable level of nuclear 




Figure 27:  The ZnPcS4-PDT induced expression of p53 and caspase 3 on MCF-7/DOX 
cells. The total and cytosolic proteins were prepared after 24 h of ZnPcS4-
PDT. An equal amount of protein (100 µg) was loaded into each lane of SDS-
Polyacrylamide gel (A) protein bands were detected by Chemi-Imaging 
system, and the grayscale was calculated with ImageJ software. The 
histograms were drawn based on the relative expression value of the 
grayscale bands corresponding to caspase 3 (B), and p53 (C) respectively in 
comparison with GAPDH.  
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The observation of p53 expression among the treatment groups suggests its role in 
tumour suppression after ZnPcS4-PDT treatment. The subunit expression of active 
caspase 3 protein (17 kDa) was not reactive. Each band on the immunoblot 
transcripts of both proteins were normalized with the housekeeping (GAPDH) gene 
and quantify to determine the relative expression shown in Figure 27 B and C for 




























DISCUSSION AND CONCLUSION 
Multidrug resistance by P-gp overexpression is one among other reasons why 
cancer recurs, and chemotherapy fails. P-gp is a membrane transporter protein that 
is organized as a biological barrier to keep harmful substrate out of the cell (Jana et 
al., 2017, Gameiro et al., 2017, Sharom, 2011, Amin, 2013). In the present study, 
we developed MCF-7 cells with increased expression of P-gp protein, herein 
referred as MCF-7/DOX cells and studied the phototoxic effect of ZnPcS4-induced 
PDT. The new developed cell line was selected in a stepwise continuous exposure 
of WT MCF-7 cells to an increasing concentration of DOX over a period of four 
months for the induction of P-gp expression. This procedure was originated from 
Howard et al., and Abuhammad and Zihlif for in vitro experimental model of a 
resistant cell line (AbuHammad and Zihlif, 2013, Howard et al., 2018). Two 
approaches namely, progressive dose-dependent and time-dependent drug 
treatment schemes have been identified to induce P-gp expression in cancer cells 
(Wang et al., 2017). Here a progressive dose-dependent approach of DOX treatment 
was used with low concentration of 2 µM until it developed stable growth before 
increasing the DOX concentration up to 64 µM. The resultant cells developed after 
stable growth with the highest DOX concentration showed characteristic features 
of cell-to-cell adhesions which suggests a possible loss of the epithelial morphology 
and transition towards mesenchymal morphology. This could be because of the 
increased vacuolation of the cell as it undergoes a cellular transformation effect of 
DOX treatment and increased expression levels of P-gp. Pasquier and colleagues 
reported similar findings on the influence of P-gp on cell volume and size. In their 
report, it was shown that cell transformation process occur during DOX exposure 
which resulted to increase the osmotic pressure, cell volume and size in DOX-
resistant variant of MCF-7 cells (Pasquier et al., 2015). This might be the reason 
for changes in the size and morphological differences seen in our study between 
WT MCF-7 and MCF-7/DOX cells. Comparably, paclitaxel a taxane molecule 
induces the same effect of P-gp expression after prolonged exposure to breast 
cancer cells (Němcová-Fürstová et al., 2016). Earlier studies have identified that 
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DOX-dependent cytotoxicity on WT MCF-7 cells were improved with 
Photodynamic combination therapy (Aniogo et al., 2017).   
The characteristic expression of P-gp transporter protein after a continuous 
exposure to anthracycline chemotherapy has been proposed as one possible 
mechanism of cancer multidrug resistance (Forster et al., 2012, Edwardson et al., 
2013). Evidence of this correlation and hypothesis was presented in enzyme 
immunoassay results of P-gp expression. There was significant difference in P-gp 
expression between normal breast (ME16C) cells, WT MCF-7, and MCF-7/DOX 
cells (Figure 13). These results agree with the findings of Tsuo et al. and Huang et 
al., which showed evidence of P-gp overexpression in chemoresistant breast cancer 
cells (Tsou et al., 2015, Huang et al., 2018).  
An immuno-imaging study using immunofluorescence further supports the 
qualitative expression of P-gp on the DOX-resistant cells. This observation was 
consistent with the findings of Iseri et al. and AbuHammad and Zihlif (Işeri et al., 
2010, AbuHammad and Zihlif, 2013). Further analysis of P-gp expression using 
flow cytometry provided an indication of cellular heterogeneity of MCF-7/DOX 
cells after immunostaining with P-gp antibody. A two-peak population of P-gp 
positive and negative cells were observed in MCF-7/DOX cells unlike the WT 
MCF-7 cells that have a dominant one peak population (Figure 15). Further 
assessment of P-gp activity on the cells using Rho123 tracer dye showed active 
efflux of the dye to prevent its accumulation within the cells. This demonstrate an 
indirect functional activity of P-gp protein (Fortuna et al., 2011). Treatment with 
Verapamil resulted to increase the influx of Rho123 dye in contrast to one without 
Verapamil. Pasquier et al. suggested this functional assay as a baseline to P-gp 
activity measurement (Pasquier et al., 2013). Taken together, our findings are 
reinforced by the studies of Jouan et al. (Jouan et al., 2016) and Forster et al. (Forster 
et al., 2012) which showed the feasibility of the use of Rho123 for evaluating the 
P-gp inhibitory potential of drugs.  
Before assessing the phototoxicity of ZnPcS4-induced PDT, examination of the 
intracellular localization and distribution of the ZnPcS4 PS was conducted to 
provide an insight into drug-cell interaction and the cell death mechanism. Results 
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from Figure 17 showed that ZnPcS4 localizes more in the prenuclear area with little 
traces of co-localization in the lysosome unlike the mitochondria. This result was 
contrary to the findings of Tynga et al. that reported increased affinity of Zinc 
Phthalocyanine to the mitochondria (Tynga et al., 2013). Also Kuzyniak and 
colleagues reported localization of Zinc Phthalocyanine PS in the mitochondria and 
nucleus of oesophageal cancer (Kuzyniak et al., 2017). Zinc Phthalocyanine PS 
affinity to the lysosome have also been reported by Shen et al. and was attributed 
to the mitochondrial expression of P-gp in MCF-7 cells which prevented their 
mitochondrial localization (Shen et al., 2012). Reports by Molinari et al. and 
Munteanu et al. also confirmed the mitochondrial P-gp expression in MCF-7 and 
E562 cells respectively thus a possible explanation for the lysosomal PS 
localization (Munteanu et al., 2006, Molinari et al., 2002).  
One of the objectives of this study was to assess the phototoxicity of the ZnPcS4 
on resistant MCF-7 cancer cells. The result of this assay in Table 5, demonstrated 
that ZnPcS4-PDT exerted effective phototoxicity on MCF-7/DOX cells in a dose-
dependent manner. Previously, we have reported similar dose-dependent toxicity 
on WT MCF-7 cells with same PS-induced PDT. Effect of similar laser fluencies 
used herein, and PS alone treatment was not significant to cause enough damage 
(Aniogo et al., 2017, Chekwube, 2017). In the current study, photocytotoxicity of 
ZnPcS4-PDT significantly increases 24 h post-treatment with 64 µM at 10 J/cm2 
and at concentrations above 16 µM with 20 J/cm2 fluence. These observations were 
similar with that of Chen and colleagues (2015) after porphyrin-based PDT on 
sensitive and multidrug-resistant human gastric cancer cells. Their study confirmed 
reduced efficacy of porphyrin-based PDT on multidrug-resistant gastric cancer cells 
compared to sensitive cell line (Chen et al., 2015). Comparable effects were 
observed on resistant MCF-7 cells with overexpressed MDR1 gene treated with 
DTP-mediated PDT (Chen et al., 2017) and polymeric mixed micelle loaded 
mitoxantrone-induced PDT (Li et al., 2017). Contrarily, results of cytotoxicity of 
ALA-induced PDT on resistant MCF-7/ADR cells did not increase in a dose-
responsive manner (Tsai et al., 2004). Studies of Wang et al. on the photodamage 
comparison of chlorin e6-mediated PDT on sensitive and resistant subtype of MCF-
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7 cells showed anti-tumour effect of reduced cell viability and increased 
cytotoxicity on both cell subtypes (Wang et al., 2016).  
The results from ATP assay also showed decreased ATP production in MCF-
7/DOX cells in a similar concentration-dependent manner like the reports of Wang 
and co-workers. Biochemical assays, treatment with the highest laser fluence (20 
J/cm2) and ZnPcS4 concentrations above 16 µM at 10 J/cm2 showed significant 
effects. A previous report from our laboratory showed a significant decrease in cell 
viability of sensitive MCF-7 cells with ZnPcS4-PDT. At concentration of 1.1 µM, 
ZnPcS-PDT was found to exert a minimal inhibitory effect on WT MCF-7 cells 
(Aniogo et al., 2017). Consequently, the newly developed MCF-7/DOX cells 
survival rate measured with trypan blue viability assay showed a minimal inhibitory 
concentration at 45 µM of ZnPcS4-induced PDT (20 J/cm2). The difference in the 
cellular effect of ZnPcS4-PDT on WT MCF-7 and MCF-7/DOX cells were 
anticipated based on the initial sensitization of the developed cell line to DOX 
chemotherapy and induction of P-gp. The cellular morphology examination 24 h 
after treatment showed a characteristic cell transformation of membrane distortion, 
rounding-up, detachment from culture plate, and floating of MCF-7/DOX cells in 
the culture medium. These features were seen at increasing ZnPcS4 doses from 16 
µM and above (Figure 20).  
The mode of cell death after ZnPcS4-induced PDT was examined using various cell 
death indicators. Firstly, we measured the translocation of the phospholipid 
membrane called phosphatidylserine to Annexin V, which is an indicator of 
apoptosis induction (Aubry et al., 1999). The result showed increased percentage 
of apoptotic cells. This observation was dependent on the laser fluence used (20 
J/cm2) and was significantly (p<0.0006) compared to the untreated control. Hoechst 
stain was used to assess the nuclear morphology after treatment and the results 
showed a gradual loss of nuclear architecture and condensation in a disorganized 
form. DNA damage and fragmentation were the hallmarks of apoptosis and their 
appearance was not observed which showed no involvement of an endonuclease 
enzyme. Cell death endonucleases mediate apoptosis through DNA damage and 
fragmentation (Basnakian et al., 2006). Reports have shown that MCF-7 cells lack 
the CASP-3 gene required for DNA fragmentation (Jänicke, 2009). This strongly 
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agree with lack of DNA fragmentation observation in this study. Expression of 
caspase 3 contributes to membrane blebbing and cleavage of caspase-activated 
DNase inhibitor that leads to typical DNA fragmentation pattern observed during 
apoptosis (Jänicke, 2009).  
The process of apoptosis are initiated via two major pathways, extrinsic (or death 
receptor) and intrinsic (or mitochondrial) (Hengartner, 2000). The latter is triggered 
by the Bcl-2 family protein and release of cytochrome c protein from the 
mitochondria. Here, the study examined the expression of proapoptotic Bax and 
antiapoptotic Bcl-2 proteins to assess their role and relationship in apoptotic 
induction of ZnPcS4-PDT treatment. Results obtained showed increased Bax to 
Bcl-2 expression with no significant release of cytochrome c which implies minimal 
photodamage of the mitochondria. This finding was contrary to that of Plonka and 
colleagues, which showed a decrease in Bax to Bcl-2 protein expression after 
Photolon-induced PDT. They conclude that apoptosis was simultaneously initiated 
by an increased Bcl-2/Bax proteins expression (Plonka et al., 2015). Another report 
by Chiu et al. suggests that Pc4-mediated PDT induced Bax translocation from the 
cytosol to mitochondria for the intrinsic apoptotic pathway activation in MCF-7c3 
cells (Chiu et al., 2003).   
Subsequent measurement of initiator caspase 8 (extrinsic) and 9 (intrinsic) proteins 
showed increased caspase 8 activity. This implies activation of caspase 8 through 
the death receptor ligand. Studies by El-Hussein et al. and Tynga et al. with Zinc 
Sulfo Phthalocyanine PS on MCF-7 cells showed induction of apoptosis through 
mitochondria-mediated pathway of caspase 9 and 3 activation (El-Hussein et al., 
2012, Mfouo-Tynga, 2013). The apoptotic cell death pathway observed in the 
present study was evidence of the extrinsic induction through phosphatidylserine 
translocation. Caspase 3 and 8 are key regulators of apoptotic response and interact 
with cysteine proteases for survival during tumorigenesis (Pu et al., 2017). Standard 
immunohistochemistry tissue microarrays for caspase 3 demonstrates that high 
expression is significantly associated with adverse breast cancer-specific survival 
(Pu et al., 2017).  
The measurement of caspase 3 in this study revealed decreased or no expression 
which can be justified by the exon deletion of CASP-3 gene in MCF-7 cells that 
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abrogate translation of CASP-3 mRNA (Jänicke, 2009). Hence, cell death response 
of MCF-7/DOX cells might be due to the lethal photodamage that was independent 
of caspase 3 expression. It is worth knowing that while most of the in vitro studies 
reported deficient caspase 3 expression, some clinical experiments relates to its high 
expression (103 out of 137(75.2%)) in invasive breast cancer (Nakopoulou et al., 
2001). Breast cancer in vitro studies have shown involvement of dysregulated 
caspase gene activity in drug resistance which can be restored through plasmid 
procaspase 3 cDNA transfection (Yang et al., 2001, Devarajan et al., 2002).  
Accordingly, the current study showed an immunoreactive detection of p53 
expression in immunofluorescence and western blotting analysis. p53 is a tumour 
suppressor protein that is frequently mutated in cancer (Hientz et al., 2017). 
Evidence have shown that PDT-mediated apoptosis in mouse embryonic fibroblast 
cells is modulated by p53 protein (Heinzelmann‐Schwarz et al., 2003). This study 
showed p53 expression which might supress the progression of resistance and thus 
initiate apoptosis in the treated MCF-7/DOX cells. In a similar study, cell death 
induced by hypericin mediated PDT on resistant colon adenocarcinoma cell HT-29 
showed the involvement of p53 in both apoptotic response and survival processes 
(Mikeš et al., 2009). This correlates with the current findings although the exact 
mechanism is not clear. It is known that DOX acts at DNA level likewise p53 
protein that form a homotetrameric transcription factor at chromosome 17 (Aubrey 
et al., 2018). Therefore, an attempt to explain the increased expression of p53 
protein after PDT would be that MCF/DOX cells that survived DOX continuous 
exposure might have their gene for p53 activated by PDT to trigger p53-dependent 
apoptosis.  
Furthermore, caspase 3 is a potential marker for predicting the response of tumour 
cells to carry out the terminal stage of apoptosis (Slee et al., 1999, Branham et al., 
2012). Herein, measurement of active caspase 3, whether by western blotting or 
catalytic activity did not correlate or show signs of intrinsic apoptotic induction but 
rather extrinsic through phosphatidylserine and caspase 8 induction. 
In conclusion, this study provided evidence that prolonged exposure of MCF-7 cells 
to DOX chemotherapy could induce increased P-gp expression, which might 
stimulate resistant phenotype development on WT MCF-7 cells. It described that 
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ZnPcS4-PDT could increase the in vitro toxicity against DOX-resistant breast 
cancer. The phototoxicity results showed decreased viability and ATP production 
whereas cellular and nuclear morphological study showed the killing efficacy of 
ZnPcS4-PDT in the form of dysfunctional and irregular nuclear morphology. The 
ZnPcS4 have shown to be a promising PS for phototoxicity of P-gp overexpressed 
resistant phenotype of cancer. The mode of cell death analysis showed an increased 
yield of apoptotic cells in a dose-dependent manner with 20 J/cm2 laser fluence 
applied. The apoptosis induced was not mitochondrial-dependent due to low 
cytochrome c release and caspase 3 expression which was supported by the 
preferential localization of ZnPcS4 PS at the lysosome rather than mitochondria. 
The involvement of caspase 8 through its expression is more prominent in the 
apoptotic process of ZnPcS4-PDT on MCF-7/DOX cells. Thus, follows the receptor 
activation of the extrinsic pathway. It is important to highlight that there are 
multiple determinants of drug responsiveness besides multidrug resistant protein, 
which needs to be considered. This study did not cover other determinant of drug 
resistance nor go in depth into the genetic expression that mediate drug resistance. 
It has been reported that inadequate ROS generation in PDT could trigger a pro-
survival autophagic response in tumour cells and possibly PDT-induced autophagy. 
Therefore, further research should focus on genic expression for different arrays of 
gene interaction that mediate resistance. Also, Beclin-1 and effect of silencing 
ATG5 autophagy gene using pharmacological inhibitors like Afilomycin A1, 
Obatoclax, Clarithromycin, and Chloroquine should be studied to rule out 
autophagy in PDT treatment of MCF-7/DOX cells. This novel strategy of 
combination treatment with inhibitors could perhaps contribute to the final solution 
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B1. List of Consumables  
 
Product name  Catalogue number Supplier/Company 
Amphotericin B A2942 Sigma Aldrich 
Anti-caspase 3 antibody  Ab3623 Sigma Aldrich 
Anti-mouse Immunoglobin IgG-HRP SC 2005 Santa Cruz 
Biotechnology 
Anti-mouse IgG-FITC  F23 Novus Biologicals 
Anti-P53 antibody CBL 404 Merck Company 
Anti-P-gp antibody Ab3366 Abcam Biotechnology  
Annexin V/PI apoptosis detection kit 556570 BD PharmingenTM 
BCA Protein Assay   Thermo Fisher 
Scientific  
Biofreezing medium 25 mL F2270 Biochrom AG 
Caspase 3, 8 and 9 Multiplex Assay kit Ab219915 Abcam  
Cell culture dish 35 mm × 10 mm 430165 Corning 
Cell Titer-Glo® ATP kits  G7571 Promega 
Centrifuge tube, 50 mL,  
PP flat top, sterile, bulk 
CR430829 Corning 
Coverslips   CG88 Lasec 
Cryogenic vial, Int-thread, 2 mL, 
round 
CR430489 Corning 
Cytochrome c ELISA KIT  KH01051 Invitrogen  





D9542 Sigma Aldrich 
Dimethyl sulfoxide (50 mL)  D8418 Sigma Aldrich  
Disposable pipette (1 mL)  BD357522 Beckson Dickinson 
Disposable pipette (2 mL)  BD357507 Beckson Dickinson 
Disposable pipette (5 mL)  BD357543 Beckson Dickinson 
Disposable pipette (10 mL) BD357551 Beckson Dickinson 
DNA fragmentation assay kit Ab66090 Abcam Biotechnology 
DNA marker HyperLadder  Bio-33053 Bioline 
Doxorubicin hydrochloride 10 mg D1515 Sigma Aldrich  
Dulbecco’s Modified Eagle’s Medium  D5796 Sigma Aldrich  
ECL Western Blotting Detection 
Reagent 
RPN2209 Amersham 
Eppendorf®, Microtubes  Z666521 Sigma Aldrich  
Eppendorf®, Microtubes  Z666505 Sigma Aldrich  
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Eppendorf®, Microtubes  Z666515 Sigma Aldrich  
Ethanol Absolute  99.99% EL 16/311 Glassworld  
Falcon (5 mL) Polystyrene round 
bottom tube (flow cytometry tubes) 
BD352054 Beckson Dickinson 
Fluoromount Aqueous Mounting 
Media 
F4680 Sigma Aldrich 
Foetal Bovine Serum 10499-044 Thermo Fisher 
Scientific  
GAPDH – Mouse monoclonal 
antibody 
MA – 15738 Invitrogen 
Goat Anti-mouse HRP SC-2005 Santa Cruz 
Biotechnology 
Goat Anti-mouse FITC Ab97050 Abcam 
Hanks Balances Salt Solution H9394 Sigma Aldrich 
Heavy tin foil 5 m × 45 cm  6001007162603 Pick n’ Pay  
Hoechst 33258 Pentahydrate (bis-
benzimide) 10 mg  
H21491 Thermo Fisher 
Scientific  
Human Simple-Step Bcl-2 ELISA Kit Ab202411 Abcam  
Human Simple-Step Bax ELISA Kit Ab199080 Abcam  
Latex gloves large powder free EV/40511 Scientific group  
MCF-7 breast cancer cell line ATCC: HTB-22 ATCC 
Microplate, 96 well, F-Bottom clear, 
sterile 2pcs/bag 
655161 Sigma Aldrich  
Microplate, 96 well, F-Bottom 
(Chimney well), white, lumitrac, high 
binding, sterile 10pcs/bag 
655074 Sigma Aldrich  
Microscope slides, frosted one end size 
25 mm × 75 mm  
S8400 Sigma Aldrich  
Mounting medium 10 mL  M1289 Sigma Aldrich 
Paraformaldehyde (4%) P6148 Sigma Aldrich 
Penicillin-Streptomycin P4333 Sigma Aldrich 
Phosphate buffered saline  P5493 Sigma Aldrich 
PVDF Membrane Immuno-Blot 162 – 0177 Bio-Rad 
Rhodamine 123 R8004 Sigma Aldrich  
Tissue culture flask 25 cm2, 
angled neck, vent,  
Sterile 
CR/423052 Corning 
Tissue culture flask 75 cm2, canted 
neck, anti-tip, vent, sterile 
CR/430641U Corning 
Tissue culture flask 175 cm2, canted 
neck, vent,  
Sterile 
CR/431080 Corning 
Triton X-100 T9284 Sigma Aldrich  




Trypan Blue T8154 Sigma Aldrich 
Universal fit pipette  
tips,100-1000 µL Bulk 
CR4868 Corning 
Verapamil  V4629 Sigma Aldrich 
Zinc (II) phthalocyanine tetrasulfonic 
acid (ZnPcS4) powder, molar mass 
898.15 g/mol 




B2. Western Blot Buffers and Reagents  
30% Acrylamide 
• 29.2g Acrylamide 
• 800 mg Bis-Acrylamide 
• Dissolve & make up to 100 mL 
10% SDS: 
• 10g SDS dissolve and make up to 100 mL using dH2O 
1.5 M Tris-HCl (pH 8.8) Separating Gel 
• 18.15g Tris base- 80 ml dH2O adjust pH 8.8 and make up to 100 mL  
0.5 M Tris-HCl (pH 6.8) 
• 6g Tris base- 80 ml dH2O adjust pH to 6.8 make up to 100 mL 
10% APS 
• 100 mg to 1ml dH2O 
10x Electrophoresis Buffer (pH 8.3) 1 L 
• 30.3 g Tris base 
• 144 g Glycine         
• 10 g SDS 
Transfer Buffer (800 mL H2O + 200 mL Methanol) 
• 3 g Tris 
• 25 g Glycine  
TBS 
• 4 g NaCl + 10 mL of 1M Tris-HCl (pH 7.6) dissolve in 500 mL of dH2O adjust pH 
to 7.6 
TBS-T 
• 500 µL Tween 20 dissolved in 500 mL of TBS and adjust pH 7.6 
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5% Blocking Solution 
• 5g milk powder dissolve in 100 ml TBS-T 
Cell Lysis Buffer 
• NaCl 150mM 
• Triton X-100 1% 
• Sodium deoxycholate 0.5% 
• SDS 0.1%  
• Tris-HCl pH 8.0, 50 mM 
2X Laemmli Sample Loading Buffer (Ready Made available in Sigma)  
• Bromophenol blue 0.2% 
• 2-mercaptoethanol 10% 
• Glycerol 20% 
• SDS 4% 
• Tris-HCl 0.125 M (pH6.8) 
 
Separation gel composition (7.5%) 
S.No 7.5% 10ml 
1 Distilled water 4.6 mL 
2 30% Acrylamide 2.7 mL 
3 1.5 M Tris pH 8.8 2.5 mL 
4 10% SDS 100 µL 
5 10% APS 100 µL 
6 TEMED 7 µL 
 
Stacking gel composition (5%) 
S.No 5% 4ml 
1 Distilled water 2.7 mL 
2 30% Acrylamide 640 µL 
3 1.5 M Tris pH 8.8 500 µL 
4 10% SDS 40 µL  
5 10% APS 40 µL 








List of Chemicals, Solutions and Media  
MCF-7 cells culture media 
Dulbecco’s Modified Eagle 
Medium (DMEM) 10 % 
complete cell growth 
medium 50 mL 
DMEM 44.0 mL 
FBS 5 mL 
Penicillin-streptomycin 0.5 mL 
Amphotericin  0.5 mL 
Dulbecco’s Modified Eagle 
Medium (DMEM) 20% 
complete cell growth 
medium 50 mL 
DMEM 39.0 mL 
FBS 10 mL 
Penicillin-streptomycin 0.5 mL 
Amphotericin 0.5 mL 
Chemotherapeutic drug and photosensitizer  
Stock 0.017 M Doxorubicin  Doxorubicin hydrochloride powder, 
molar mass 579.98 g/mol  
10 mg  
0.5% DMSO 1 mL  
Stock 0.0005 M ZnPcS4  Zinc (II) phthalocyanine tetrasulfonic 
acid (ZnPcS4) powder, molar mass 
898.15 g/mol 
0.0006 g 
0.01 M PBS  1.25 mL 
Sterilization  
70% Ethanol  Absolute ethanol  70 mL 
Autoclaved distilled water 30 mL 
Experiments  
0.5% DMSO   Dimethyl sulfoxide ≥ 99.9%, molecular 
weight 78.13 g/mol, liquid form  
5 µL 
Autoclaved deionized water  995 µL 
1x Annexin V-FITC/PI 10x binding buffer  1.7 mL 
Autoclaved distilled water  17 mL 
Powdered Propidium Iodide  250 mg 
1x binding buffer 1 mL 
ATP Cell Titre-Glo reagent  ATP Cell Titre-Glo buffer 1 mL 
ATP Cell Titre-Glo substrate  0.007 g  
LDH reconstitute  LDH assay buffer 1.2 mL 
LDH substrate mix 0.012 g  
10 mg/mL Hoechst stock  Powdered Hoechst  0.001 g 
Autoclaved distilled water 1 mL 
4% Paraformaldehyde 
solution 
Paraformaldehyde powder   40 g 
0.01 M PBS 1 L 
0.01 M PBS Phosphate buffered saline powder  1 packet  
Autoclaved distilled water  1 L  
0.5% TritonX-100 Trixton-100 0.5 mL 






List of Equipment used 
Product name Catalogue number  Supplier/Manufacturer 
680 nm Laser PSU-III-LED  
(MRL-III- 680 – 800 mW).  
Optoelectronics. Tech. 
Co. LTD.  
Power Meter Field Mate 125JO7R National Laser Centre 
Light Microscope Olympus  CKX41 Wirsam 
BD Accuri Flow Cytometer 
C6 
FACS Diva version 6.1.3 BD Biosciences 
Fluorescent Microscope Axio observer Z1 Carl Zeiss 
Multilabel counter Victor 3 1420 Perkin Elmer 
Countess Automated Cell 
Counter 
C10227 Invitrogen 
Multi Timer  91500-013-bt Manufactured in France  
Plate washer  F92430 Bio-Rad 




Z 206 A HERMLE Labortechnik 
GmbH, 78564 Wehingen 
Chemi-Doc MP Imaging 
system  
731BR03103 Bio-Rad 
Power Pac Basic 041BR158211 Bio-Rad 
Mini-protean Tetra Cell 552BR002247 Bio-Rad 
Snap i.d. 2.0 Protein 
Detection System 
S003314 Merck Germany  






































E2. Cell viability  
 
The percentage of viable cells were calculated using the following formula:  
After addition of 10 µL of suspended cells to 10 µL of 0.4% trypan blue solution, 
cells are placed in a disposable slide for counting on the Countess automated cell 
counter. The amount of dead and live cells are then calculated automatically per ml. 
Amount/ml x suspension volume (mL) = Total cells in suspension 
Total amount of cells – Total dead cells = Total viable cells 
Total viable cells/ 100 = % viable cells 
E3. Cell seeding for culturing  
A cryopreserved ampule of cells were initially cultured on a 25 cm2 small flask. 
The cells were cultured in a monolayer until confluent. When passaging cells to a 
bigger flask e.g. 75 cm2 the amount of viable cells calculated (C1) are then used in 
the following calculation to ensure cells will grow towards confluence in an 
acceptable amount of time to avoid minimal seeding density which can lead to cell 
death. 
Calculation: Proposed seeding ratio of 5 x 105 cells (seeding amount) 
If total amount of viable cells are 1.31 x 107/ mL and cells are suspended in 5 mL 
of media, then: 
1.31 x 107 cells x 5 mL = 6.55 x 107 cells in 5 mL 
6.55 x 107 cells/ 5 x 105 (seeding amount) = 131           
5 mL/ 131 = 0.038 mL 
Thus, the volume of cells from the suspension needed to be seeded in the 75 cm2 
flask will be 0.038 mL suspended cells + media. 
 
E4. Cell seeding for cryopreservation  
 
According to the requirements for cell freezing, the number of viable cells to be 
frozen is 2 x 106 per flask containing 1 mL of biofreeze in a 1.5 mL cryovial.     
Therefore, the calculation is as follows: 
After calculation of number of viable cells (C1), the cells are centrifuged in order 
to obtain a cell pellet.  
Total viable cells e.g. 1.31 x 107/ 2 x 106 = 6.55 
99 
 
Thus, 6.55 mL of biofreeze freezing medium will be added to the cell pellet for 
suspension. (Can round up to 7 mL) 
 
E5. Working concentration of Doxorubicin from stock concentration of 
0.0172 M. 
 
• A stock solution of 0.017 M Doxorubicin was made in 0.5% DMSO. 
• The working concentration of 0.1 - 1 µM was made in 50 mL sterile centrifuge 
tube containing growth medium using the following calculation: 
• C1V1 = C2V2 
 
Table E1: Doxorubicin (stock) volumes that were added for different 
concentrations.  
 
0.017 M Doxorubicin  
Working concentration tested in 
MCF-7 cells dose response assay 
Calculated volume of Doxorubicin working 
concentration made in sterile centrifuge tube 
containing 50 mL of media 
0.2 µM Doxorubicin 0.58 µL 
0.4 µM Doxorubicin 1.16 µL 
0.6 µM Doxorubicin 1.74 µL 
0.8 µM Doxorubicin 2.32 µL 
1.0 µM Doxorubicin 2.89 µL 
 
E6. Working concentration of ZnPcS4 Photosensitizer from stock 
concentration of 0.0005 M 
 
• A stock solution of 0.0005 M ZnPcS4 PS was made. 
• The culture plate contained 3 mL of growth culture medium and the working 
concentration was calculated using:  








Table E2: ZnPcS4 PS (stock) volumes that were added for different concentrations.  
 
0.0005 M ZnPcS photosensitizer  
Working concentration tested in MCF-
7 cells dose response assay 
Calculated volume of ZnPcS PS added 
to the culture plate of cells containing 
3 mL of media 
2 µM ZnPcS4 PS 12 µL 
4 µM ZnPcS4 PS 24 µL 
8 µM ZnPcS4 PS 48 µL 
16 µM ZnPcS4 PS 96 µL 
32 µM ZnPcS4 PS 192 µL 
64 µM ZnPcS4 PS 384 µL 
 
E7. Working concentration of 10 µg/mL Hoechst working solution from stock 
concentration of 10 mg/mL Hoechst 33258 fluorescent dye stock solution  
 
• A stock solution of 1.0 mg/mL of Hoechst 33258 fluorescent dye was made.  
• Culture plate contained 1 mL of complete growth culture medium.  
• Thus, to add a working concentration of 10 µg/mL of Hoechst working staining 
solution, the below formula was used:  
C1V1 = C2V2   
E8. Inhibitory concentration 
 
• Inhibitory concentration measures the effectiveness of a compound to inhibit 
biochemical and biological function.  
• Inhibitory concentration was calculated using linear regression equation (Y = 
MX + C) from excel scatterplot graph of ZnPcS4-mediated PDT dose response 
of 20 J/cm2 group. In the equation, Y = percentage inhibition, M = coefficient, 
X = concentration, and C = constant.  
• For ZnPcS4, linear regression equation Y = -0.5432X + 74.35. when Y was 
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